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Breast cancer is one of the most common form of disease for women. While early 
detection leads to good prognosis, the mortality is still high owing to metastasis and 
chemoresistance. Our group very recently identified DDX20 as a crucial player in the 
metastasis of breast cancers, where DDX20 increases the invasiveness of breast cancers 
through activation of Iκκ complex, leading to activation of NF-κB and its downstream 
targets MMP9 and CXCR4 (Hay and Shin et. al., manuscript under revision). This 
discovery makes DDX20 a potential therapeutic marker in invasive breast cancers.  
 
Recently, we have further uncovered the potential to target DDX20 by statins, a 
drug commonly used for treating hypercholesterolaemia. We showed that simvastatin and 
lovastatin can downregulate DDX20 in a dose-dependent manner in invasive breast 
cancer cell line MDA-MB-231 and BT-549. As DDX20 is pivotal for activation of NF-
κB and the invasiveness of breast cancers, we hypothesize that statins-induced DDX20 
downregulation will lead to the abrogation of metastasis and inactivation of the NF-κB 
pathway. We also postulate that statins might downregulate DDX20 (i) canonically via 
the mevalonate (MVA) pathway, and (ii) non-canonically via the regulation of 
microRNAs (miRNAs). For the first part of the hypothesis, MVA rescue experiments 
confirmed that Statins-induced DDX20 downregulation is mediated through the MVA 
and geranylgeranyl pyrophosphate (GGPP) pathway.  
 
In parallel, in silico analysis was performed on the 3’-UTR of DDX20; miRNA-
125a/125b, miR-221/222, miR-641 and miR-655 were selected for further validation 
studies in a panel of normal breast epithelial and breast cancer cell lines. We showed 
through transient transfection studies that miR-222 could be a potential regulator of 
DDX20. Interestingly, we also demonstrated for the first time, that upon statins treatment, 
the expression of miR-222 was upregulated, which suggests that statins might 
downregulate DDX20 through miRNAs. However, the manipulation of miR-222 does not 
affect statins-mediated DDX20 downregulation. We also showed that manipulation of 
ix 
 
miR-222 is crucial for and affects statins-induced apoptosis, which imply that miR-222 
might be targeting a MVA pathway gene or an apoptotic gene.  
 
In conclusion, we showed that statins can downregulate DDX20 via the canonical 
MVA pathway and the non-canonical pathway through mediation of miRNA. Therefore, 
our work contributed to the exploitation of DDX20 as a potential therapeutic marker for 
statins and the understanding of the functional relevance of miR-222 to statins-induced 
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Chapter 1 : INTRODUCTION 
 
1.1 Breast cancers 
 
1.1.1 Breast cancers statistics  
 
 
Breast cancer is one of the most common forms of female malignancies in 
the world. Each year, about 1.3 million women are diagnosed with breast cancer 
and approximately 460,000 of them die from the disease. In the United States, 
234,580 cases were diagnosed and 40,030 deaths were recorded in 2012. 
According to American authorities, the lifetime risk of women developing breast 
cancer is 12% (Cancer Facts & Figures 2013, http://www.cancer.org). On the 
other hand, in Europe, one woman is diagnosed with breast cancer every second 
(Annals of Oncology 2012). According to the latest information obtained from 
Cancer Research UK, breast cancer is the most common cancer in UK. In 2010, 
more than 49,500 women were diagnosed with breast cancer, about 136 new cases 
per day. They reported a 6% increase in breast cancer incidence in the last ten 
years (http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/breast 
cancer/cancerstats-key-facts-on-breast-cancer). On the other hand, male breast 
cancer incidence rate is very low and accounts for approximately 0.5 – 1% of all 
breast cancers reported [1-4], although most male breast cancer cases are 
associated with a worse prognosis.  
 
 
Shin and colleagues analysed data from 15 countries in East Asia 
(including China, Korea, Japan and Taiwan) and Southeast Asia (the Philippines, 
Singapore, Thailand) for the period of 1993 to 2002. They showed that breast 
cancer incidence rates are on the rise rapidly across all countries, from 0.9% in the 
Philippines to 7.8% in Korea. In fact, the most rapid increase in breast cancer 
incidence rate was reported in Korea. They also reported a slight decrease in 
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breast cancer mortality in Hong Kong and Singapore for all age groups 
investigated after 1990, except for women aged 70+, possible due to better health 
care, early diagnosis and treatment [5]. 
 
 
In Singapore, breast cancer is the most common cancer in females, 
accounting for 29.7% of all female cancers. According to Jara-Lazaro and 
colleagues, about 1100 new cases and 270 deaths are reported in Singapore every 
year.  The age-standardized rate of breast cancer in Singapore is 60 / 100,000, the 
highest in Southeast Asia. The age-standardized breast cancer incidence rate in 
Singapore is increasing continuously, possibly due to an aging population, 
lifestyle choices, rapid urbanization, environmental changes and improvement in 
socio-economic status [6].  
 
 
1.1.2 Classification of breast cancers  
 
Breast cancer is a heterogeneous disease which constitutes multiple 
entities associated with diverse biological, morphological, clinical characteristics, 
disease courses and responses to specific treatments. Variations in breast cancers 
observed differ from patient to patient and even within the same patient.  Both 
scientific and clinical communities have struggled to come up with a single 
comprehensive and systematic classification system but to no avail. Currently, 
breast cancers are usually classified based on their histopathological features, 









1.1.2.1 Classification by histological types 
 
 
By definition, classification by histological types refers to classification 
based upon morphological and cytological patterns exhibited by the tissues 
according to their growth pattern [7].  
 
 
Under this category, the most common type of breast carcinoma is the 
invasive ductal carcinomas not otherwise specified (IDC-NOS) or of no special 
type (IDC-NST) [8], which accounts for up to 75% of all breast cancers, followed 
by invasive lobular carcinomas, which make up 15% of total cases . These are 
tumors that fail to exhibit specific characteristics that allow them to be grouped 
under any category. The remaining breast cancer cases belong to breast cancer 
special types. According to the World Health Organization, there are at least 17 
distinct histological special types, Due to their low prevalence and the lack of 
investigation, not much is known about the special types [9]. As such, there is 
currently no diagnostic and tailored therapy catered for these patients.  
 
 
1.1.2.2 Classification by histological grading  
 
 
Histological grade, on the other hand, should not be confused with 
histological type. Instead, grade is an assessment of the tumor‟s aggressiveness 
based on the degree of differentiation and proliferative activity of tumor tissues 
when they are compared with normal breast epithelial cells. Conventionally, 
histological grade, lymph node (LN) and tumor size have been used as the three 
main prognostic determinants in routine practices in the classification of early 
stage breast cancers. The most well-known system recommended by professionals 
world-wide is the Nottingham Grading System (NGS), which was modified from 
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the Scarff-Bloom-Richardson grading system first proposed by Bloom and 
Richardson in 1957. The prognostic relevance of NGS has been replicated and 
validated across many independent studies. Since then, NGS has been combined 
with lymph node (LN) status and tumor size to form the Nottingham Prognostic 
Index (NPI) [10].   
 
 
NGS is applied based on the evaluation of the following three criteria in 
breast tissues: 1) degree of tubule or gland formation, 2) nuclear pleomorphism, 
and 3) mitotic count [10]. The tissues are scored from 1 to 4, with 1 being well 
differentiated and defined tissues and 4 being poorly differentiated tissues. 
Basically, it is a relatively inexpensive and hence affordable screening method as 
it requires only a properly prepared hematoxylin-eosin-stained tumor tissue 
section, which will be assessed by a trained pathologist. Due to compelling 
evidences that NGS can accurately predict tumor behavior, it has been adopted 
into algorithms such as „Adjuvant! Online‟ to determine the use of adjuvant 
chemotherapy [11].  
 
 
1.1.2.3 Classification by staging  
 
 
The most commonly used staging system for treatment decisions is the 
Tumor (T), Nodal (N), Metastatic (M) staging, jointly maintained by the 
American Joint Committee on Cancer (AJCC) [12] and the International Union 
for Cancer Control (UICC). Briefly, the TNM looks for the presence of tumor (T), 
and whether the cancer has spread to the lymphatic glands (N) or if the cancer has 
spread to other parts of the body, i.e. metastasis (M). As mentioned earlier, TNM 
is typically used in conjunction with NPI to assess the overall treatment and 
prognosis of a patient. The tissues are usually scored from 0 to 4. Stage 0 refers to 
a pre-cancerous condition, stages 1,2 and 3 to tumors confined to a local invasion 
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and regional lymph nodes and stage 4 to a highly aggressive and metastatic tumor 
(http://www.cancer.gov/cancertopics/factsheet/detection/staging).   
1.1.2.4 Classification by Hormone Receptor Status  
 
 
The presence or absence of hormone receptors is commonly used as 
prognostic biological markers and targeted treatments in breast cancers. Hormone 
receptors are routinely assessed by immunohistochemistry (IHC) stainings in 
clinical practice. The main markers assessed are Estrogen Receptor (ER), 
Progesterone Receptor (PR) and human epidermal receptor 2 (HER2). The “five-
marker method” is yet another popular panel used in defining intrinsic breast 
cancer subtypes. This panel includes ER, PR, HER2, Epidermal Growth Factor 
Receptor (EGFR) and Cytokeratin 5/6 (CK5/6) [13].  
 
 
Generally, ER- and PR-positive breast cancers account for 75-80% of 
breast cancer cases, while HER2-positive breast cancers make up 15-20% of the 
total cases [14]. The advantage of the presence of hormone receptors is that they 
can be exploited as a therapeutic molecular target. For instance, Selective 
Estrogen Receptor Modulator (SERM), such as Tamoxifen [15, 16], and 
aromatase inhibitors [17-19] are used to treat ER-positive breast cancers, while 
the anti-HER2 monoclonal antibody Herceptin/Trastuzumab is used to target 
HER2-positive breast cancers.  
 
     
The breast cancer subtypes that do not express any of the hormone 
receptors are collectively known as the triple-negative breast cancer (TNBC). 
This category of breast cancer presents a challenge to clinicians because they are 
highly aggressive and have no known targets for treatment to date [14]. TNBC is 
a heterogeneous disease and should not be used synonymously with the term 
“basal-like breast cancers” as it includes both the basal-like and non-basal-like 
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breast cancers. The five-marker method [13, 14, 20] is used in identifying TNBC 
as only TNBC express EGFR and/or CK5/6. Recent work by Lehmann and 
colleagues have further divided TNBC into six subtypes, namely basal-like 1 (BL-
1), basal-like 2 (BL-2), immunomodulatory (IM), mesenchymal (M), 
mesenchymal stem-like (MSL) and luminal androgen receptor (LAR). This 
analysis has shed some light on the complexities of TNBCs and the availability of 
therapeutic targets for TNBC, which will be discussed in Section 1.1.3 .  
 
  
 Interestingly, Ding et. al. reported the first comprehensive genomic 
analysis of a basal-like breast cancer performed using massively parallel 
sequencing technology [21]. They analyzed the genome of a primary breast tumor 
and compared it both to a brain metastasis sample developed from recurrence and 
a mouse xenograft tissue derived from the injection of a primary breast tumor into 
an immunodeficient mice. They found that the primary breast tumor had more 
mutations and higher mutation frequencies. This suggests that the primary tumor 
came from a pool of heterogeneous cells, which had undergone clonal evolution 
or selection during the process of metastasis and xenograft. It is also worth noting 
that the basal-like breast cancer genome has about 3 to 4 fold more single 
nucleotide variations (SNVs) than the genome of acute myeloid leukemia (AML), 
which further strengthens the observation that the basal-like breast cancer (or 
TNBC) is a highly complex disease [21]. It also implies that personalized 
medicine or treatment for breast cancer patients might not be so straightforward.  
 
 
1.1.2.5 Classification by Molecular Subtypes   
 
 
 Over the past decade, the advancement and availability of high-throughput 
microarray-based technologies has made genomic profiling more readily 
accessible. Emerging studies on large-scale studies of breast cancer cohorts have 
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cast new light on the disease, leading to the identification of the molecular 
subtypes of breast cancers. Pioneer study came from Perou and colleagues, who 
analyzed 65 surgical specimens of human breast tumors from 42 different 
individuals. According to their report, breast cancers can be classified into 5 
subtypes, namely the luminal A subtype which expresses higher levels of ER-
alpha (ER-α), luminal B subtype which has decreased levels of ER-α and worse 
prognosis, basal-like subtype which corresponds to and includes TNBC, ERBB2 
positive subtype which overlaps with IHC-defined HER2-positive tumors, and 
normal-like subtype which is associated with phenotypes of normal breast 
epithelial tissues [22].  
 
 
 Other studies have also attempted molecular profiling of breast cancers; 
one study proposed the classification of ER-α positive breast cancers into four 
subtypes, while another one suggested a model for luminal breast cancers where 
ER-regulated elements and proliferation are inversely correlated. More recently, 
other molecular subtypes within the ER- α subtypes have also been revealed. 
Claudin-low subtype which is linked to an aggressive phenotype and poor 
prognosis has been reported. Evidence suggests that this subtype of breast cancer 
is linked to breast tumor initiating cells and epithelial-to-mesenchymal (EMT)-
linked signatures [23-25]. On the other hand, a separate study also reported the 
molecular apocrine class which is enriched in ER- α negative and HER2-positive 
tumors [25-28].  
 
 
Although the identification of molecular subtypes has unraveled new 
possibilities of exploiting previously unknown targets as prognostic or therapeutic 
markers, there remain many obstacles and limitations. The heterogeneity of the 
breast tumor samples used in the high-throughput studies, the instability of the 
molecular subtypes identified and the management of breast cancer patients based 
on the molecular subtypes have raised concerns. Also, the study conducted by 
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Perou and colleagues might not have been comprehensive and inclusive as the 
authors only investigated samples from IDC-NSTs and two invasive lobular 
carcinomas. Luminal A and luminal B subtypes were distinguished based on their 
ER-regulated and proliferation-related genes [22]. A later study demonstrated that 
the two subtypes could be arbitrary which makes this criteria too arbitrary.  
 
 
There is currently no consensus and there are huge overlaps between the 
different classifications. Tumors of different histological grades have shown 
different genomic and transcriptomic profiles, which raise the possibility that 
tumors of different grades might be different diseases as opposed to a progression 
from a benign tumor to a malignant one. We should also bear in mind that cost for 
molecular profiling is many times greater than histological grading. Other than the 
cost-effectiveness, advance It is also important to bear in mind the lack of 
systematic histological investigations of special types of breast cancers due to the 
low prevalence and limited availability of fresh or frozen tissues. Also, since the 
adoption of NGS, there has been greater agreement among different observers and 
clinicians regarding the classifications of breast cancers. However, the 
subjectivity of histological grading remains an issue, rendering the prospect of 
molecular profiling welcoming.  
 
 
1.1.3 Therapies for triple negative breast cancers  
 
 
 Unlike hormone receptor positive breast cancers which have direct targets 
that can be exploited for treatment purposes, such an option is not readily 





 Chemotherapy is still the first line form of treatment administered to 
patients diagnosed with TNBC, although it has produced mixed results [20, 29-
33]. Due to the similarities in the pathology of TNBCs and BRCA-related breast 
cancers, it was speculated that TNBCs might be sensitive to drugs that cause 
DNA damage [20]. Some evidence suggests that approximately 10% of basal-like 
breast cancers actually arise from BRCA1 mutation carriers [34].  As such, 
platinum-containing compounds have been used in the treatment of TNBCs even 
though the effect was modest. In highly aggressive TNBCs, platinum salts are 
used in combination with other drugs such as anthracycline and/or taxane 
compounds. These regimens have produced relatively positive outcomes [20]. 
 
 
In the more recent years, PARP inhibitors have been used for the 
treatment of TNBCs. However, it is not surprising that more breast tumors might 
harbor disruption in BRCA or BRCA-related pathways since it is responsible for 
one of the key DNA repair pathways [35-38]. The usage of PARP inhibitors alone 
or in combination with other drugs such as gemcitabine or carboplatin [20] have 
shown remarkable efficacy of pathological complete response (pCR) ranging 
from 30% to 62% in the treatment of TNBC with improved progression-free and 
overall survival.   
 
 
 Other inhibitors which target common pathways, such as EGFR inhibitors, 
PI3K pathway inhibitors and androgen receptor inhibitors are currently being 
explored [39]. EGFR inhibitors such as cetuximab have been used in combination 
with carboplatin [39, 40]. Activation of EGFR targets such as PI3K, may be a 
limiting factor to some poor responses from EGFR inhibitors. As such, PI3K 
inhibitors such as NVP-BEZ235 are used in TNBCs where EGFR is 
overexpressed. Androgen receptor is an emerging target currently under 
investigation. Some TNBCs are positive for androgen receptors despite being 
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negative for ER and PR. There is currently an ongoing clinical trial for 
bicalutamide for ER and PR double negative breast cancers.  
 
 
1.2 DEAD box superfamily of RNA helicases 
 
1.2.1 Structure and Function of DEAD Box Proteins 
 
 
RNA helicases are enzymes that are involved in RNA metabolisms, where 
they function as RNA chaperones, preventing the formation of undesirable intra- 
or inter-molecular structures during cellular processes by unwinding RNA, or 
assisting in the formation of RNA-protein complexes via ATP hydrolysis. DEAD-
box protein, first discovered in 1989, is a subgroup of RNA helicases which 
belong to the RNA helicase superfamily II [41]. Most of the characterisation of 
the DEAD-box protein was done in Saccharomyces cerevisiae, where 25 DEAD-
box proteins were identified. In humans, however, this subfamily of RNA 
helicases is made up of an additional 11 DEAD-box proteins [41-43].  
 
 
The DEAD-box family has nine conserved core motifs [41, 44] which are 
grouped into two different domains. Domain 1 consists of Q-motif, Motif-I, Ia 
and Ib, II and III while Domain 2 is made up of Motif-IV, V and VI. To date, little 
is known about Motif-Ia, Ib, III, IV and V but the other motifs are well-studied. 
DEAD-box protein got its name from motif II, the characteristic D-E-A-D (Asp-
Glu-Ala-Asp) motif. Motif II, together with Motif I (Walker A Motif), Q-motif 
and motif VI, are essential for the ATP binding and hydrolysis. All the motifs 
forming the core element of the DEAD-box proteins are conserved throughout 
prokaryotes and eukaryotes. On the contrary, the N-terminal and C-terminal 
sequences flanking the core motifs exhibit no sequence homology and growing 
studies have revealed that they are very often targets of post-translational 
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modifications. This versatility seems to confer specificity and allow the DEAD-
box members to interact with many other proteins, making DEAD-box members a 
group of multifunctional proteins. Interestingly, in vitro studies have 
demonstrated that the core helicase domain does not recognize substrates based 
on sequence specificity. Rather, the flanking N- and C-terminal domains as well 
as the interactions between the helicase with large ribonucleoprotein (RNP) 
complexes may help to confer substrate specificity [38].  
 
 
DEAD-box proteins participate in multiple levels of RNA processing, 
including pre-mRNA splicing [45-47], ribosome biogenesis, RNA transport, 
translation initiation [48-51], organelle gene expression and RNA decay [52]. 
There is also some preliminary evidence to suggest that DEAD-box proteins are 
involved in transcription. DEAD-box proteins are unique compared to other RNA 
helicases, in that they are very inefficient in unwinding long helices. Instead, they 
prefer substrates that are between 25 – 40 bps [39]. This observation was obtained 
from in vitro studies, which have limitations and may not be an accurate reflection 
of the actual unwinding activity of RNA helicases in vivo. Another more plausible 
explanation would be that the DEAD-box family members favor local unwinding 
and dissociation of proteins from RNA. This seems to suggest that DEAD-box 
helicases may be important regulators of various small RNAs. While the inclusion 
of the nine conserved domains automatically classifies a protein as a DEAD-box 
member, the enzymatic activity of RNA helicases has only been tested in a few.  
 
 
Some of the relatively well-studied DEAD-box proteins include DDX1, 
DDX2, DDX3, DDX5, DDX20 and DDX54. DDX1 was originally identified due 
to its overexpression in the childhood tumors retinoblastoma and neuroblastoma 
[53]. It is a gene located in chromosomal region 2p24 and has been found to 
interact with RelA (p65) subunit of NF-κB [54]. It is the only human DEAD-box 
protein which has a Sprouty (SPRY) domain [55].Exposure to ionizing radiation 
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leads to increasing phosphorylation of DDX1 by ATM, suggesting a role for 
DDX1 in the DNA double-strand break repairs [56]. Another study has identified 
DDX1 as an important regulator of the HIV Regulator of virion (Rev) protein, 
where the overexpression of DDX1 led to increased viral production and its 
knock-down resulted in the re-localization of Rev [57, 58]. On the other hand, 
DDX2, otherwise known as eIF4A, is a well-studied DEAD-box member. eIF4A 
plays a key role in the initiation of translation, unwinding RNA and relieving 
secondary RNA structures, thus allowing ribosomal access during translation [59, 
60] . Other than its role in translation initiation, eIF4A also interacts with the 
tumor suppressor Programmed cell death receptor-4 (Pcdc-4). The binding 
between the two inhibits the activity of eIF4A [61].  
 
 
DDX5 (p68) is perhaps the most well characterised DEAD-box family 
member. It is a nuclear protein which exhibits RNA helicase and annealing 
activity [62]. DDX5 can de-stabilize the binding between the U1 small nuclear 
ribonucleoprotein particle (snRNP) and the 5‟ splice site (5‟ ss). It is also involved 
in a plethora of helicase-independent processes, which include transcriptional 
regulation, proliferation, differentiation and DNA damage response. Preliminary 
studies showed that DDX5 can interact with the transcriptional co-activator 
CREB-binding protein (CBP/p300) as well as RNA polymerase II [63]. Among 
other things, post-translational modification occurs frequently on DDX5. DDX5 
can be SUMOylated by PIAS1, leading to its increased interaction with HDAC1. 
On the other hand, phosphorylation of DDX5 enables DDX5 to interact with B-
catenin and the activation of the transcription of its downstream genes cyclin D1 
and c-Myc, which leads to increased proliferation [64, 65].  
 
 
DDX17 (p72) is structurally and functionally closely-related to DDX5It is 
usually found in a heterodimer with DDX5. As such it is not surprising that 
DDX17 was also isolated in a complex with u1 snRNP [66]. DDX5 and DDX17 
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work hand-in-hand in the regulation of some of the most important cellular 
processes. For instance, both DDX5 and DDX17 are responsible for the alternate 
splicing of c-H-ras and CD44 [47]. Perhaps more interesting is the discovery of 
the involvement of both DDX5 and DDX17 in the regulation of estrogen receptor-
alpha (ER-a). DDX5/17 acted as a transcriptional co-activator of ER-a, inducing 
its activity by modulating interactions between ERα, AF1 and the AF2 coactivator 
complex through direct binding [67]. However, one must keep in mind that the 
two still have independent functions which cannot be compensated. For instance, 
siRNA knock-down of DDX17 showed that the interaction between DDX5 and 
p53 is not shared by DDX17 [68]. In all cases, the interactions between DDX5/17 
and their partners are established entirely through the C-terminal only while the 
helicase domain seem to have no part to play.  
 
 
On the other hand, much of the information available on DDX6 (otherwise 
known as p54) came from its Xenopus counterpart. It is known to participate in 
translational regulation and function in various cytoplasmic bodies. An example 
would be the discovery of the interaction between DDX6 and Ago1 and Ago2 




1.2.2 DEAD-box proteins and cancers 
 
 
The roles of DEAD-box proteins in tumorigenesis are still not established. 
However, emerging studies have unraveled the roles of some DEAD-box proteins 
in the development and progression of human cancers. DDX1 was frequently 
found to be co-amplified with MYCN in retinoblastoma and neuroblastoma [69, 
70]. However, some studies showed that this co-amplification does not happen in 
every MYCN amplification. So far, attempts to investigate the role of DDX1 in 
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tumor progression have been made but nothing conclusive has been found. More 
recently, immunohistochemistry (IHC) staining of samples from early stage, 
node-negative breast cancer patients have shown that patients with high levels of 
DDX1 demonstrated better local control, distant metastasis-free survival and 
overall survival. On the other hand, the involvement of DDX6 in carcinogenesis 
was first discovered in a diffuse large B-cell lymphoma DDX6 is well-known to 
be overexpressed in colorectal cancers [71]. 
 
 The roles of DDX5 in cancer progression are one of the most established 
in the DEAD-box family. DDX5 promotes epithelial-mesenchymal transition 
(EMT), the most important first step towards metastasis, through the activation of 
Snail, by promoting the dissociation of HDAC1 from the promoter of Snail1 [72]. 
On the other hand, Bates and colleagues found that DDX5 was recruited to the 
promoter region of p53 target genes upon DNA damage. They also showed that 
DDX5 knock-down abrogated the expression of p53 target genes in response to 
DNA damage [73]. While the observations were not yet validated in vivo, the p53 
studies were conducted in several cancer cell lines including SAOS-2 and U2OS 
(osteosarcoma), H1299 (lung carcinoma) as well as MCF-7 (breast 
adenocarcinoma). More recently, Sapourita and colleagues uncovered a new 
oncogenic role of DDX5. They identified DDX5 as a p53-independent target of 
the tumor suppressor p19ARF. Using  Arf-deficient mouse cells, the authors 
showed that the localization of DDX5 was restricted to the nucleolus and that 
interaction between DDX5 and nucleophosmin was severely affected (NPM), 
which then led to the inhibition of ribosome biogenesis [68]. This seems to imply 
that DDX5 is a robust transcriptional coactivator which can function both as a 
tumor suppressor and oncogene under different cellular contexts. 
 
DDX5 is overexpressed in a range of solid tumors and blood cancers, 
which include colon, prostate, breast and acute lymphoblastic leukaemia [74]. 
One of the most interesting discoveries made was the identification of the 
DDX5:ETV4 fusion protein in prostate cancer, although the exact function of this 
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novel fusion protein has yet to be uncovered [75]. In breast cancers, DDX5 
regulates the progression of cell cycle from the G1 to S phase by promoting the 
binding of RNA polymerase II to the promoter regions of E2F1-regulated genes. 
This was corroborated by the frequent amplification of DDX5 locus in breast 
cancers. Depletion of DDX5 also led to the sensitization of a subset of breast 
cancers to trastuzumab treatment. Furthermore, combined knock-down of DDX5 
and DDX17 inhibited the proliferation of cervical carcinoma cells.  
 
1.2.3 DEAD-BOX proteins as regulators of miRNA processing and function 
 
 
It is not uncommon for DEAD-box proteins to regulate miRNA processing 
and function. Fukuda and colleagues discovered that p68 and p72 (DDX5 and 
DDX17 respectively) are indispensable for the processing of ribosomal (rRNA) 
and a subset of 94 miRNAs. In their study, they showed that p68 and p72 are co-
immunoprecipitated in a complex with the mouse Drosha (mDrosha). Using an in 
vitro miRNA processing assay, they demonstrated that p68 and p72 are essential 
for the conversion of a subset of primary miRNAs into precursor miRNAs. They 
performed clustering analysis on the subset of miRNAs but did not find any 
correlation between the functions of the affected miRNAs and the biological 
functions of p68 and p72 [48]. Given the fact that only a subset of miRNAs is 
affected, it is tempting to speculate that Drosha forms different complexes with 
different RNA-binding proteins in the regulation of primary miRNA processing.  
Another possibility is that there may be functional redundancy of p68 and p72 
with other miRNA processing subunits; in this regard, other closely-related family 
members of the DEAD-Box protein, such as DDX20, might also come into play. 
 
 
Recently, it has been revealed that Ago2 associates with only one strand of 
the miRNA duplex. This suggests that there are other factors which might help to 
confer specificity to the loading of miRNA duplexes onto RISC. Studies 
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conducted on the loading of siRNA duplexes onto RISC implicated the function 
of RNA Helicase A in unwinding the siRNA duplexes. In a similar manner, the 
loading of miRNAs could be performed or facilitated by other RNA helicases. A 
study by Salzman et al. showed that a recombinant p68 can unwind let-7 miRNA 
precursor duplex in vitro. They also found that transient knock-down of p68 
abrogates let-7-directed silencing, suggesting that RNA-binding protein is 
important for miRNA function [49]. Interestingly, another earlier study showed 
that DDX6 interacts with Ago1 and Ago2, and that the depletion of DDX6 leads 
to global translational repression [50].  
 
 
1.2.4 Discovery and expression of DDX20  
 
 
DDX20 was first identified in a study screening for cellular factors that 
bind to the Epstein-Barr virus (EBV) nuclear proteins EBNA2 and EBNA3C. 
Both EBNA2 and EBNA3C bind to different regions of DDX20, the former at 
amino acids (aa) 121-213 and the latter at aa 534-778 [76]. The helicase activity 
of DDX20 was confirmed through an ATPase activity assay. The authors also 
performed northern blot analysis and looked at the expression of DDX20 in a 
series of human cell lines and tissues. Most human cell lines express DDX20; the 
neuroblastoma cell line SK-NS-H and three melanoma cell lines express high 
levels of DDX20. Intriguingly, the expression levels of DDX20 in cell lines do 
not coincide with the primary human tissues. In normal tissues, expression of 
DDX20 was highest in the testes and tonsils, although its expression was also 
detected in colon, skeletal muscles, liver, kidneys and lungs. However, no signals 
were detected in brain, prostate, stomach and peripheral blood lymphocytes. Like 
other RNA helicases, it is unclear how DDX20 recognises its substrates or if there 




Interestingly, a recent study has casted some light on the functional 
implications of the interactions between DDX20 and the EBV proteins. 
Interaction between EBNA3C and DDX20 maintained and enhanced the protein 
stability of DDX20. Remarkably, the authors uncovered the direct interaction of 
DDX20 and p53. They demonstrated that this interaction is indispensable for the 
EBNA3C-mediated inhibition of p53 transcriptional activity. Furthermore, they 
showed that knock-down of DDX20 abrogated the EBNA3C-mediated inhibition 
of p53-induced apoptosis, evident from the reduction in colonies. Thus, the 
authors suggested a model where DDX20 assisted EBNA3C in the proliferation 
of EBV infected cells, thus driving carcinogenesis [77].  
 
 
In another study conducted by Charroux and colleagues, DDX20 was 
cloned and characterized as Gemin3, a new component of the survival motor 
neurons (SMN) complex. SMN complex exists both in the cytoplasm and nucleus; 
in the cytoplasm, SMN complex partners Gemin2 and is mainly involved in the 
assembly of small ribonucleoproteins (snRNP) particles while in the nucleus, 
SMN complex is pivotal for pre-mRNA splicing and the arrangement of the 
splicing machinery. Gemin3 and SMN complex can be co-immunoprecipitated 
together in a huge complex together with Gemin2, and they were found to co-
localize in nuclear gems. In addition, the authors also found that Gemin3 interacts 
directly with the core components of the snRNP SM components. It is still unclear 
exactly what role Gemin3 play in the splicing process, but the importance of 
Gemin3 is reiterated in clinical data obtained from smooth muscular atrophy 
(SMA) patients. In SMA patients who harbor the SMNY272C or exon 7 deletion, 
the interaction between Gemin3 and SMN complex was disrupted. As a 
consequence, this affected the formation of the SMN complex, which could be the 






1.2.5 DDX20 as a transcriptional repressor  
 
 
Instead of its inherent helicase activity, many studies have reported the 
role of DDX20 as a transcriptional regulator, predominantly, a transcriptional 
repressor [41-45].      
 




One of the unique roles that DDX20 plays is its involvement in 
SUMOylation, which was first described by Lee and colleagues (2005). 
SUMOylation is a post-translational modification characterised by the addition of 
Small Ubiquitin-related Modifier (SUMO) proteins to their substrates through a 
pathway that shares similarities with ubiquitination. According to Lee et al., 
DDX20 interacts directly with the nuclear receptor steroidogenic factor-1 (SF-1) 
by binding to a hinge region on SF-1 through its C-terminal. SF-1 controls 
endocrine signaling and the biosynthesis of steroid hormones. While many 
SUMOylated proteins were repressed through Histone Deacetylases (HDACs), 
further analysis showed that SUMOylation of SF-1 was not mediated through 
HDACs. Instead, the interactions between DDX20 and SF-1 enhanced the 
SUMOylation of SF-1 by E3-SUMO ligases PIASy and PIASxα, leading to the 
repression of SF-1 and the relocalization of SF-1 to nuclear bodies. Intriguingly, 
the study also revealed that the C-terminal of DDX20 contains an autonomous 
intrinsic transcriptional repressive activity, although this activity very much 







1.2.5.2 DDX20 represses Egr-2-induced transcription  
 
 
Based on a yeast two-hybrid study, DDX20 was also identified as an 
interacting partner of all four members of the early growth response (Egr) family 
of transcription factors. Egr transcription factors are involved in several important 
cellular responses such as proliferation, differentiation and apoptosis, but their 
most significant role would be the myelination of the peripheral nervous system 
and segmentation of the vertebrate hindbrain. DDX20 represses the activation of 
Egr2 and the Egr2-mediated induction of the endogenous insulin-like growth 
factor 2 (IGF-2) gene. In addition, DDX20 also represses Egr2-targeted promoters 
derived from FGF2, LH-𝛽, fasL and EphA4 genes. The mechanism of repression 
seemed to involve HDAC activity, but treatment with the HDAC inhibitor 
Trichostatin A (TSA) showed that this dependence on HDAC is dependent on the 
promoter specificity. In fact, upon TSA treatment, the repression of FGF was 
alleviated while the effect on EphA4 was only partial. Consistent with the 
observations from the interaction between DDX20 and SF-1, the C-terminal of 
DDX20 is sufficient for the repression of the trans-activation of Egr2 and the 
induction of its target genes [79]. 
 
 
1.2.5.3 Interaction of the Ets repressor METS with DDX20 is required for 
anti-proliferative effects of METS 
 
 
 Although the interaction between DDX20 and p53 blocks p53-induced 
apoptosis, another study on the Ets repressor METS/PE1, conducted by 
Klappacher and colleagues [80] revealed interesting and contradicting role of 
DDX20. The authors showed through elegant experiments that METS can 
distinguish between monomers and composite Ets binding sites through its 
interaction with DDX20 during terminal differentiation. Using macrophage as a 
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model, they showed that DDX20 could be isolated as a binding partner of METS 
and that the two proteins could be co-immunoprecipitated together. They further 
demonstrated that interaction of METS with DDX20 is indispensable for the 
antiproliferative effects of METS [80]. Interestingly, they also showed that METS 
is associated in a histone deacetylase complex (HDAC) together with N-CoR and 
Sin3A through the C-terminal of DDX20 . This seems to suggest that DDX20 can 
switch between tumor suppressive and tumor promoting roles under different 
cellular contexts, something which warrants further investigation.  
 
 
1.2.5.4 FOXL2 interacts with DDX20 and induces apoptosis  
 
On the other hand, DDX20 was also identified as the first FOXL2-
regulated protein. FOXL2, a family member of the forkhead transcription factor, 
was first associated in the blepharophimosis-ptosis-epicanthus inversus syndrome 
type I, i.e. premature ovarian failure in women due to mutations in the FOXL2 
gene which can be passed on through dominant inheritance. On its own, FOXL2 
induces apoptosis in Chinese hamster ovary cells and rat granulosa cells, but with 
co-expression of DDX20, there is a synergistic apoptotic response. Interestingly, 
overexpression of DDX20 alone did not seem to have any effects on the cells [81].  
 
1.2.6 DDX20 and its potential role in cancer 
 
 
While the roles of other DEAD-box proteins in cancers have been quite 
well-established for some time, DDX20 was only first implicated in cancer when 
a recent protein microarray showed its up-regulation in mantle-cell lymphoma 
[82].  We thus proceeded to screen a series of normal and breast cancer cell lines 
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and demonstrated that DDX20 is indeed strongly upregulated only in 
invasive/metastatic breast cancer cell lines. This was confirmed by 
immunohistochemistry staining of patients‟ tumor tissues, where DDX20 was also 
shown to be upregulated in metastatic breast cancers. The abrogation of DDX20 
in invasive breast cancer cells rendered the cells incapable of invasion and 
migration, implicating DDX20 in the metastasis pathway in breast cancer. 
Furthermore, DDX20 levels were found to correlate with MMP9, a family 
member of the matrix metalloproteinases and a downstream target of NF-κB. 
Incidentally, we also discovered that, under genotoxic stress, DDX20 is essential 
for the SUMOylation of NEMO, leading to the activation of NF-κB and hence 
MMP9, which is frequently activated and overexpressed in invasive breast 
cancers. Taken together, our data demonstrates that DDX20 plays a role in the 
metastasis of breast cancer and therefore presents itself as an attractive therapeutic 
target in invasive/metastatic cancers (Hay and Shin et al., under revision).  
 
 
1.3 miRNA: biogenesis, processing and function   
 
 
MicroRNAs (miRNAs) are small, noncoding RNAs which can be found 
from viruses [83] to plants [84] and animals [85]. MiRNAs were first discovered 
as small regulatory RNAs in Caenorhabditis elegans; where lin-4 and let-7 were 
first identified [86, 87]. Subsequently, homologs of let-7 were discovered in other 
mammals, suggesting the importance of these small RNAs in the regulation of 
cellular processes [87, 88].   
 
 
Mammalian miRNAs bind to the 3‟-untranslated region (3‟UTR) of their 
target mRNAs, leading to mRNA deadenylation, mRNA cleavage or protein 
translation inhibition [89]. MiRNAs are first transcribed by RNA polymerase II 
into 3 - 5 kb long primary transcripts [90, 91], which are then processed into 
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hairpin precursor miRNAs by Drosha [92] in the nucleus and exported into the 
cytoplasm by the Ran-GTPase exportin-5 [93]. In the cytoplasm, precursor 
miRNAs are further processed into ~22 nt mature double-stranded miRNAs by 
Dicer [88, 94]. Of the two strands, only one strand will be selected as the 
functioning mature miRNA whereas the other strand (denoted as miRNA*) will 
be degraded.  The mature miRNA is loaded onto a micro-ribonucleoprotein 
(miRNP) complex, otherwise referred to as miRNA-induced silencing complexes 
(miRISCs) (Figure A). The most well-characterized and studied component of 
this RNA-protein complex are members of the Argonaute (Ago) family, which 
comprise many proteins [95]. Apart from Ago proteins, other co-factors, effector 
molecules and RNA-binding proteins are also required for the proper function of 
the miRNP [96].  
 
 
Each miRNA can have many targets; its specificity is determined by the 
„seed sequences‟, typically the 2nd to 7th position of the 5‟ miRNA, which are 
complementary to the 3‟-UTR of its target mRNA. Depending upon the degree of 
complementarity of the miRNA-mRNA pairing, when miRNA binds onto its 
target mRNA, the RISC complex will induce degradation of the mRNA (perfect 
complementarity) or inhibit the translation of protein (imperfect complementarity) 
[97, 98]. Most miRNAs function as mild rheostats, fine-tuning the expression 
levels of mRNAs instead of making huge changes.   Since the binding between 
miRNA and mRNA does not have have to be in perfect complementarity, each 
miRNA can have up to 150 targets which then makes them one of the largest class 
of mediators regulating about 30% of proteins [99]. They are involved in various 
essential cellular processes, such as apoptosis [100], proliferation [100], 
differentiation and stem-cell renewal [101]. Hence, it is not surprising that 
deregulation of miRNAs is frequently implicated in many diseases, including 






Figure A. The miRNA processing pathway. Primary miRNA (pri-miRNA) is 
transcribed by RNA polymerase II or III and cleaved by the microprocessor 
complex Drosha–DGCR8 in the nucleus. The resulting precursor hairpin (pre-
miRNA is exported from the nucleus by Exportin-5–Ran-GTP. In the cytoplasm, 
Dicer/TRBP complex cleaves the pre-miRNA hairpin to its mature length. The 
functional strand of the mature miRNA is loaded together with Argonaute (Ago2) 
proteins into the RNA-induced silencing complex (RISC), where it guides RISC 
to silence target mRNAs through mRNA cleavage, translational repression or 
deadenylation (Reprinted by permission from Macmillan Publishers Ltd: Nature 
Cell Biology, [103], Copyright 2009).  
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Increasing reports have shown that miRNA signatures are exploited 
rapidly in stratifying and characterizing various epithelial cancers. One of the first 
miRNA profiling done on human cancers revealed the global downregulation of 
miRNAs in tumors. Various high-throughput miRNA profilings have also shown 
that miRNAs are deregulated in multiple tumors types, such as breast [104-106], 
pancreatic [107], gastric [108], brain [109, 110], blood [111, 112], lung [113], 
liver [114, 115] and colorectal cancers [116]. More than a quarter of known 
miRNAs were shown to be dysregulated in cancers, which imply the importance 
of miRNAs in tumorigenesis and cancer progression.  
 
 
Some of the more prominent miRNAs include let-7, miR-21, miR-155, 
miR-181b, miR-221/222 and miR-17-92. Let-7 is the first miRNA that was 
discovered and its family members are very well-studied. Various studies have 
shown that let-7 is dysregulated in brain, blood, breast, colon, intestinal, and lung 
cancers . Some of the mRNA targets of let-7 are also frequently implicated in 
cancers, such as HRAS [117], CASP3 [118], DICER1[119, 120], HMGA2 [121] 
and MYC [122, 123]. MiR-21 is the most commonly dysregulated miRNAs in 
both solid and hematological tumors [124]. It plays a myriad of functions in the 
cancers, including proliferation, apoptosis, invasion and metastasis.  
 
 
Interestingly, miR-155 is a unique miRNA which can control the 
transcriptome of the activated myeloid and lymphoid cells in protective immunity 
ranging from inflammation to immunological memory [125-128]. As such, 
disruption in the processing or expression of miR-155 is frequently associated 
with malignant transformation; miR-155 has been found to be frequently 
upregulated in the cancers of the brain [129], thyroid [130, 131], intestinal tracts 





Similarly, mir-181b is also frequently found to be dysregulated in brain 
[133], intestinal tracts and hematological tumors too [134, 135]. The mir-221/222 
cluster has also been found to be upregulated in many cancers, including breasts 
[136-140], multiple myelomas [141] and gliomas [142, 143]. Functional studies 
have confirmed the roles of miR-221/222 in important cellular processes, with the 
most widely-studied being the involvement of miR-221/222 in the manifestation 
of invasion and metastasis [144, 145].  
 
 
1.3.1 MiRNAs and their implications in breast cancers 
 
 
Just like other cancers, miRNAs are also heavily dysregulated in breast 
cancers. Ever since Iorio and colleagues  first reported miRNA profiling in breast 
cancers [104], more than 20 other papers on comprehensive miRNA profiling and 
breast cancer subtype classification have been published to date.  
 
Molecular profiling of breast cancers has been instrumental in making new 
discoveries on the dysregulation of miRNAs in breast cancers [104, 106, 146-158]. 
Expressions of several hundreds of miRNAs have been examined between breast 
tumor samples or serum and either paired adjacent non-tumor samples, unpaired 
non-tumor or normal breast samples, utilizing different profiling technologies 
such as bead-based flow, reverse transcription quantitative real-time PCR (qRT-
PCR), deep-sequencing or miRNA microarrays. In one of the studies conducted,  
miRNA profiling was used to distinguish between the luminal and basal epithelial 
subsets of tumors [159]. In others, miRNAs have been successfully applied to 
differentiate breast tumor subtypes based on their hormone status [106, 154]. All 
these studies showed that miRNA profiling provided added knowledge and depth 
to the disease which can benefit patient management. This leads to the possibility 
of using miRNAs as potential diagnostic and prognostic markers. While the 
overlaps between the various studies are at best minimal, these observable 
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differences could be due to the inherent histological heterogeneity that were 
overlooked, as well as selection bias of the breast cancer subtypes used in the 
studies due to geographical and ethnicity,  limitations in sample collections and 
other confounding factors.  
 
 
To complement studies based on miRNA profilings, independent miRNA-
specific studies have identified numerous roles of miRNAs in the tumorigenesis 
and progression of breast cancers. For instance, miR-125a/125b targets ERBB2 
and ERBB3 and were reported to be downregulated in HER-2 overexpressing 
breast cancers [160]. Many studies have also uncovered the oncogenic potential of 
miR-21; miR-21 is involved in the regulation of proliferation, apoptosis, invasion 
and metastasis. Interestingly, EZH2, the polycomb group (PcG) protein which 
trimethylates histone H3 lysine 27 (H3K27) is targeted by miR-214, which is 
found to be deleted in approximately 24% of primary breast tumors [161, 162]. 
Mir-200 family has been shown to maintain the integrity of the epithelial 
phenotype of breast epithelium and is frequently downregulated or lost in invasive 
and metastatic breast cancers [163-166]. Intriguingly, studies have suggested the 
„bivalency‟ of some miRNAs, in which they exhibit opposing characteristics of 
tumor-suppressive and oncogenic potential. A good example would be the miR-
17-92 family which is well-known for controlling and fine-tuning the proliferation 
of breast cancers cells under different contexts [167].  
 
 
Accumulated evidences have also shown that there is a sub-group of 
miRNAs that are involved specifically in the metastasis of cancers, and these 
miRNAs are collectively termed as “metastamirs” [168].  
 
 
Metastamir is one of the mostwell-characterised groups of miRNAs. 
Multiple players have been identified, where the interplay between the metastasis-
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promoting and metastasis-suppressing miRNAs defines the outcome of the 
progression. Some of the more well-studied metastasis-promoting miRNAs 
include miR-10b [169], miR-21 [162, 170], miR-103/107 [171], miR-221/222 
[144, 145], and miR-373/miR-520c [172], while the metastasis-suppressing 
miRNAs include miR-200 family members, miR-31 [173-175], miR-335 [176, 
177], miR-126 [178] and miR-206 [179] , to name a few.  
 
 
The involvement of miRNAs in metastasis was first revealed by the 
discovery of miR-10b. Twist, a master regulator of metastasis, induces the 
transcription of miR-10b, which in turn inhibits HOXD10, a homeobox factor that 
helps to maintain cells in a differentiated state and an inhibitor of RhoG, the 
effector of metastasis. The inhibition of HOXD10 by miR-10b would lead to cell 
migration and invasion [169].  
 
 
MiR-21 also plays an indispensable role in mediating the invasion and 
metastasis of breast cancers through downregulation of metastatic mediators such 
as TIMP1, PDCD4 and Maspin [180]. Analysis of breast cancer patients showed 
that the expression of miR-21 is correlated to the aggressiveness of the tumors, 
lymph node metastasis and shortened survival time. Intriguingly, the expression 
of miR-21 is upregulated in breast cancers by several important oncogenic cell 
signaling pathways, such as TGF-β [181, 182] and MAPK [183, 184].  
 
 
MiR-373/520c works in a similar manner; mir-373/520c targets CD44 for 
degradation, leading to increased invasion [172]. Recent findings also revealed 
that miR-221/222 cluster, which targets ER-α, promotes EMT in breast cancers 
[144, 145, 185]. MiR-221/222 exerts its effect by the attenuation of E-cadherin 
through inhibiting the GATA family transcription repressor TRPS1. TRSP1 
inhibits the expression of ZEB2, another master regulator of metastasis. This is 
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substantiated by the overexpression of miR-221/222 in the highly aggressive ER-
α negative breast cancer cell lines such as MDA-MB-231 and BT-549 [144, 145].   
 
 
It was shown that global miRNA expression levels were downregulated in 
human cancers. Cancer cells can inhibit the expressions of miRNAs by interfering 
with the processing and/or maturation of miRNAs. Indeed, miR-103/107 was 
identified as a negative regulator of Dicer. The expression level of miR-103/107 
was found to be inversely correlated with the expression of Dicer in breast cancer 
patients. Overexpression of miR-103/107 in the poorly metastatic 168FARN and 
SUM149 breast cancer cells potentiated the migration and invasion abilities of 
these cells while silencing of miR-103/107 in the highly metastatic 4T1 cells 
resulted in the reduced migratory and invasion capabilities of the cells. 
Remarkably, the authors revealed that miR-103/107 modulates metastasis through 
activation of EMT by controlling the expression of miR-200 family members 
[171]. 
 
The miR-200 family members are one of the more well-known negative 
regulators of metastasis; miR-200c in particular, inhibits ZEB1/2, one of the main 
transcription factors which inhibit the expression of E-cadherin and other genes 
that control cell polarity and epithelial identity [186-188]. This is corroborated by 
the low expression of miR-200 and E-cadherin in the highly metastatic MDA-
MB-231 cells which expresses high levels of ZEB1. In addition, overexpression 




Another important metastasis-suppressing miRNA was identified by 
Tavazoie and colleagues. They showed that miR-335 inhibits Tenascin C, 
interfering with the interactions between the cells and extracellular matrix 
essential for the formation of a proper tumor microenvironment [105]. miR-335 
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also targets Sox4 [190], a transcription factor that is pivotal in progenitor cells 
development and in the regulation of Wnt [191], TGF-β [192], Notch and 
Hedgehog [190].   
 
Interestingly, the notion of metastamir is quite debatable. In some 
instances, some of the miRNAs mentioned are involved in multiple processes 
during progression of tumors, not just metastasis. This question was beautifully 
addressed through the discovery of miR-31 by Valastyan and colleagues [174, 
175, 193], which has helped to shed some light on the “bona fide metastasis-
intervening” miRNAs. In fact, miR-31 presents itself as an interesting 
“multitasker” which is involved in multiple steps of the invasion-metastasis 
cascade. The authors have revealed that miR-31 is involved in epithelial-
mesenchymal transition (EMT), local invasion and anoikis resistance of breast 
cancer cells. Some of the targets of miR-31 include FZD3, ITGA5, M-RIP, 
MMP16, RDX and RhoA [194]. They also showed that that miR-31-
overexpressing cells injected into mice formed tumors that were highly 
encapsulated but not locally invasive, which supported the notion that miR-31 is 
already involved in the earlier steps of the invasion-metastasis cascade. The 
manipulation of the levels of miR-31 does not alter the size or affect the 
proliferation of the tumor but only affecting the metastatic potential of the cells.  
 




1.4.1 Statin as a Pleiotropic Agent  
 
 
Statin is a class of drugs which are widely prescribed for treating 
hypercholesterolemia [195, 196].  Statin act as structural analogs of 3-hydroxyl-3-
methylglutaryl (HMG)-CoA reductase (HMGCR), the first committed enzyme of 
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the cholesterol synthesis, or Mevalonate (MVA) pathway (Figure B), thus 
blocking the rate-limiting step of the conversion of HMG-CoA to MVA [195, 197] 
and the synthesis of downstream products of MVA pathway. There are about 
eight known members of Statin family, which include simvastatin, lovastatin, 
fluvastatin and atorvastatin. Simvastatin and lovastatin are both prodrugs derived 
from fungi, and they have to be converted to their active forms in the liver [198, 
199]. On the other hand, fluvastatin and atorvastatin are both synthetic drugs that 
are already active in their parent form. Due to differences in their 
physicochemistry and metabolism, the efficacy and the distribution of Statin in 
the human body are different for the different drugs in the family. For instance, 
lipophilic Statin such as lovastatin and simvastatin cross the blood-brain barrier 
easier than fluvastatin [200, 201].  
 
 
As a result of its cholesterol-lowering properties, clinical studies have 
shown that the usage of Statin has successfully reduced mortality and morbidity 
associated with coronary artery disease (CAD), while also aiding in the 
prevention of CAD [202]. More recent studies also suggest that prolonged 
treatment with Statin reduces the occurrence and recurrence of coronary 
syndrome and similar diseases [203]. In addition, growing studies and evidences 
have suggested that the cholesterol-independent effects of Statin seem to benefit 
patients with other diseases. In fact, Statin also possess anti-inflammatory and 
immune-modulatory properties, inhibit monocyte recruitment, improve 
endothelial function, possess anti-hypertensive effects, decrease proteinuria and 
progression of kidney diseases as well as have positive effects on bone 














1.4.2 Statin as inhibitors of the MVA pathway 
 
 
Statin inhibit the first rate-limiting step of the MVA pathway, thus 
effectively blocking the downstream pathway. MVA pathway involves addition of 
isoprenoid units to produce various intermediates and metabolites, including 
geranylgeranyl pyrophosphate (GGPP), farnesyl pyrophosphate (FPP), cholesterol, 
dolichol, isopentenyl tRNA and ubiquinone, many of which are important for 
different cellular functions [195].  Cholesterol, for instance, is an essential 
building block of the cellular membrane structure and is important in maintaining 
its integrity. Cholesterol also regulates the activity of membrane-bound 
transporters, ion channels, signalling molecules and transport vesicles as well as 
serves as a precursor in the synthesis of steroid hormones and bile acids 
[207]. Dolichol is a carrier molecule of oligonucleotidesaccharides involved in the 
production of glycoproteins. Ubiquinone is a primary component of the electron 
transport chain which generates ATP from mitochondrial (aerobic) respiration 
[208]. GGPP and FPP are isoprenoid intermediates that are used for post-
translational modifications of cellular proteins in a process called prenylation, 
where a geranylgeranyl moiety or a farnesyl moiety is added to the C-terminus of 
the protein. Some of the well-known prenylated proteins include Ras and many 
small GTP-binding proteins such as Rab, Rac and Rho families [209]. In fact, 
prenylation is essential for the activity of these proteins; prenylation facilitates the 
translocation of these proteins from the cytosol to the plasma membrane, as well 





As cholesterol is an important player in the regulation of many cellular 
processes, the metabolism and synthesis of cholesterol must be tightly yet 
robustly regulated. Regulation of the cholesterol level and lipid homeostasis in 
cells is mediated by a group of transcription factors called Sterol-regulatory 
element binding protein (SREBP). SREBP is involved in the expression of genes 
that are involved in lipid biosynthesis (HMG-CoA Reductase) and uptake (Low-
Density Lipoprotein (LDL) – Receptor). Inactive SREBP precursors which are 
embedded in the membranes of the endoplasmic reticulum are usually bound to 
the cholesterol sensor SREBP cleavage activating protein (SCAP). Upon Statin 
treatment, cholesterol synthesis is inhibited. Upon sensing low cholesterol levels, 
SREBP tethers on to SCAP and is transported to the vesicles in Golgi, where 




Figure B. Schematic diagram of the MVA Pathway. The MVA pathway 
produces many metabolites and end-products which are important for many 
cellular functions. Isoprene units incorporated into compounds such as GGPP 
and FPP are important for synthesis of cholesterol and prenylation of Ras and 










1.4.3 Statin and its Anti-cancer Properties 
 
 
1.4.3.1 Effects of Statin in Cancer 
 
 
More recently, many studies have shown that Statin exhibit anti-cancer 
effects [211] through various mechanisms, predominantly by inducing cell cycle 
arrest [211-213] and apoptosis [214-217], reducing metastatic potential [211, 218, 
219], and reversion of multidrug resistance [220, 221]. Different statin families 
differ in their anti-cancer potential, anti-proliferative and pro-apoptosis effects. In 
fact, the efficacy of Statin is largely dependent on their hydropathic properties; 
Statin that exhibit lipophilic properties exhibit better anti-tumor potential, 
possibly due to the fact that they are able to cross the cell membrane. Campbell 
and colleagues examined the effects of various Statin on the prevention of the 
growth of breast cancer cells. Not surprisingly, the lipophilic Statin lovastatin, 
simvastatin and fluvastatin are cytotoxic against breast cancer cells while the 
hydrophilic pravastatin has no effect at all. Two other separate studies, one on 
ovarian cancer cells [201] and the other on myeloma tumor cells [200] also 
confirmed the observation.    
 
 
Extensive in vitro studies have been conducted on various leukemia cells 
and solid tumors of different origins. In blood cancers, for instance, the efficacy 
of Statin on acute myeloid leukemia (AML) is one of the most studied and 
34 
 
documented ones [214, 216]. Based on various published studies, Statin are very 
effective in killing cancer cells originated from AML either by sensitizing them to 
chemotherapy or inhibiting adaptive cholesterol response. These studies revealed 
that AML patients who originally had high expression levels of HMGCR or low 
density lipoprotein receptor (LDLR) were resistant to conventional chemotherapy. 
For these patients, combination therapy with Statin might prove to be clinically 
valuable [222]. Statin-induced cell death is further confirmed through the 
blocking of protein geranylgeranylation by GGPP inhibitors (GGTI), which 
mimics the effect of Statin. On the other hand, the usage of FPP inhibitors (FTI) 
was less efficient. Interestingly, simvastatin has been shown to induce apoptosis 
through extrinsic pathway in chronic lymphocytic leukemia (CLL) cells [217]. 
Several other studies also showed that Statin could induce apoptosis in primary 
cells derived from CLL, hairy cell leukemia and immunoblastic cell leukemia. 
Interestingly, in a study conducted on the sensitivity of 59 tumor cell lines of 
human origin to lovastatin, acute myeloid leukemia cells but not acute 
lymphocytic leukemia cells was sensitive to lovastatin [215].  
 
 
In addition, the same study also showed lovastatin-induced apoptosis and 
cytotoxicity in cell lines derived from various solid tumors such as 
medulloblastoma, rhabdomyosarcoma, choriocarcinoma, squamous cell 
carcinomas of the head, neck and cervix [215]. Perhaps the most prominent anti-
cancer effects of Statin come from studies conducted in lung cancer cells. The 
effects of Statin are pervasive in both small cell lung carcinoma and non-small 
cell lung carcinoma. In a study conducted by Mantha and colleagues, they found 
that lovastatin could inhibit certain types of lung carcinoma cells where epidermal 
growth factor receptor (EGFR) was highly expressed. Further studies also 
demonstrated that lovastatin could inhibit EGFR autophosphorylation which was 
induced by EGF and the combination therapy of lovastatin and gefitinib led to 





Similar to cancer cells derived from AML, colorectal cancer cells also 
displayed high levels of HMGCR and LDLR in comparison to normal cells, 
which suggests that the cholesterol (or mevalonate) pathway might be involved 
here as well. Treatment of colon cancer cells with mevastatin induced the 
expression of p21 which led to growth arrest [224]. On the same token, there is 
also evidence which showed that Statin induced expression of p21, independent of 
p53, in prostate carcinoma cell lines. Prostate cancer cell lines were also 
demonstrated to be more sensitive to cholesterol-depletion induced cell death in 
comparison to their normal counterparts [225]. Statin have been shown to inhibit 
the proliferation of prostate carcinoma cell lines PC-3 and LNCaP [226]. In a 
separate study, lovastatin was shown to induce senescence and cell cycle arrest in 
prostate cancer cell lines. Intriguingly, this lovastatin-induced senescence can be 
rescued by overexpression of the small GTPase RhoA [227].  In vivo studies using 
SCID mice also showed a positive correlation between cholesterol levels and 
protein tyrosine phosphorylation in lipid rafts isolated from xenograft tumors. The 
same study also showed that increased cholesterol level is accompanied by 
reduced apoptosis and increased AKT phosphorylation [228].   
 
 
In breast cancer cells, flavastatin, simvastatin, lovastatin and pravastatin 
have also been tested and similar apoptotic and cytotoxic effects were observed. 
Much of the effects of Statin on breast carcinoma cells were executed through the 
abrogation of the MEK/ERK pathway and the inhibition of the DNA-binding 
activity of NF-κB and adapter protein 1 (AP-1) [229]. One study showed that 
simvastatin could induce cell cycle arrest and apoptosis in both ER-α 
positive/wild type p53 MCF-7 cells and ER-α negative/mutant p53 MDA-MB-
231 cells, which suggests that Statin deliver their effects independent of estrogen 
receptor status and p53 expression. Interestingly, the authors showed that Statin-
induced apoptosis is mediated through the JNK pathway, which can be abolished 
by treating the cells with the specific JNK inhibitor SP600125 [230].  There were 
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also evidences which point to the important roles that are played by nitric oxide 
and arginase-dependent pathways in Statin-induced pro-apoptotic effects in the 
more resistant MCF-7 breast carcinoma cell lines [231].  
 
 
 While in vitro and in vivo animal model studies of Statin‟ anti-cancer 
effects look promising, pre-clinical trials have provided mixed results, most likely 
due to differences in tumor types. For instance, statin treatment yielded positive 
results in advanced hepatocellular carcinoma [232], acute myeloblastic leukemia 
[233] and non-metastatic rectal cancer [234] while no beneficial effects were 
observed in pediatric cancers [235], advanced gastric cancers [236] and chronic 
lymphatic leukemia [237]. The meta-analysis conducted by Kuoppala and 
colleagues also showed that Statin did not really protect patients against certain 
cancer risks (lung, breast and prostate), but offered some protective effect against 
stomach cancer, liver cancer and lymphoma [238]. The confusion and 
inconsistencies observed are not surprising due to a few reasons. Firstly, most of 
these pre-clinical studies were retrospective studies initially designed for patients 
who had hypercholesterolaemia or cardiovascular-related diseases. One has to 
remember that a large number of these studies are meta-analyses, which imply 
that they are mainly observational. As such, the statin types, dose, duration of 
administration, duration of follow-up, patients demographics and other parameters 
would differ across all these studies. More importantly, one also has to take into 
consideration the relatively shorter period of Statin administration versus the 
longer latency of carcinogenesis or relapses. In some cases, Statin might need to 
be continuously administered to certain cancer patients for maximum efficacy. 
Thus, these pre-clinical studies might not be a true measure of the efficacy of 
Statin.   
 





Importantly, to date, there are no clinical studies on breast cancers even 
though it has been widely reported that Statin induces apoptosis and reduces the 
aggressiveness of breast cancer cells in vitro [211, 229-231]. The existing 
clinically relevant studies are largely retrospective, where mixed results were 
observed due to various confounding factors and untraceable cases.  
 
 
For instance, one retrospective study observed a 51% reduction in breast 
cancer risks when women who are above 58 years old were administered Statin, 
while another one found no protective effect of Statin on breast cancers [238]. 
Another group reported the association of lipophilic statin usage (atorvastatin, 
lovastatin and simvastatin) and the decrease in the proportion of receptor-negative 
breast cancers [239]. Women‟s Health Initiative Research Group reported that the 
overall Statin use was not associated with invasive breast cancer incidence and the 
duration of use of Statin do not affect invasive breast cancer risks. However, the 
study also highlighted the possibility of the association of lower invasive breast 
cancer incidences (18% reduction) with the use of hydrophobic Statin [240]. 
There are still discrepancies among the different studies, although the general 
trend seems to point to the direction that usage of Statin protects patients from 
invasive breast cancer risks. In a study conducted on African Americans, who 
have higher risks of developing TNBCs, usage of lipophilic statin was associated 
with a reduction in the proportion of receptor-negative breast cancers across all 
age-adjusted ethnic groups. This raises the possibility of exploiting Statin as a 
potential new prevention approach for African Americans [239].  
 
1.4.4 Anti-cancer Mechanisms of Statin 
 
 
Inhibition of Mevalonate pathway by Statin also inhibits farnesylation and 
geranylgeranylation of Ras and many small GTPases respectively. As a 
consequence, Statin can also inhibit the several malignant phenotypes of cancer 
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cells. One of the most prominent effects is the induction of apoptosis in Statin-
treated cells [225, 229, 241-244]. In fact, multiple studies have showed through 
GGPP or FPP add-back experiments, that addition of GGPP to Statin-treated cells 
completely rescues the apoptotic phenotype while addition of FPP has very little 
effect [217]. This phenomenon is further substantiated by Mevalonate add-back 
experiments and treatment of cells with geranylgeranyl transferase inhibitor 
(GGTI) and/or farnesyl transferase inhibitor (FTI). When cells are co-treated with 
Mevalonate and Statin, Mevalonate inhibited Statin-mediated apoptosis. On the 
same token, GGTI but not FTI treatment of cells resulted in a phenotype that 
mimicked Statin-mediated apoptosis. This suggests that Statin inhibit the 
apoptosis of cells through the inhibition of the geranylgeranylation of proteins 
[201, 218].  Moreover, Statin-treatment seem to induce apoptosis through both the 
intrinsic and extrinsic pathways. Some studies have shown that Statin activate the 
upregulation of pro-apoptotic proteins Bax and Bim as well as the downregulation 
of the anti-apoptotic protein Bcl-2 [244, 245]. On the other hand, Statin also can 
induce the activation and cleavage of caspase proteases, such as caspase-7 and 
caspase-3 [201, 218].  
 
 
More interestingly, Statin can reverse the resistance of cells to doxorubicin 
in malignant mesothelioma cells, through the inhibition of RhoA GTPase activity 
and subsequently the activation of NF-κB. This causes an upregulation of nitric 
oxide (NO), which induces the nitration of ATP-binding cassette (ABC) 
transporters P-glycoprotein (PGP) and multidrug resistance-associated protein 
(MRP)-3. Nitration of the transporters inhibits export, which results in the 
retention of intracellular content of doxorubicin and hence the reversion of the 
drug-resistant phenotype [246].  
 
 
Statin can also inhibit invasive and metastatic potential of cancers. It has 
been shown that Statin can inhibit migration and invasion in many cancer cell 
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lines, including pancreatic cancers [247], breast cancers [248], glioma [249], and 
melanoma cells [250]. In vivo mouse model studies also confirmed the anti-
metastatic potential of Statin in colon carcinoma cells [251], melanoma cells 
[250], renal cancer cells [252] and breast carcinoma cells [248]. Rescue 
experiments by addition of GGPP but not FPP reversed the anti-metastatic effect 
of Statin, which suggest that geranylgeranylated proteins might play a part in this. 
RhoA and RhoC are among the geranlygeranlyated proteins which play pivotal 
roles in invasion and migration by controlling cell motility [211, 253]. The anti-
metastatic effects of Statin could be mediated through the inhibition of RhoA/Rho 
Kinase/NF-κB pathway and the downstream targets of NF-κB such as urokinase 
plasminogen activator tissue factor (uPA) and metalloproteinase-9 (MMP9) in 
invasive breast cancer cells [211]. Further, Statin have been shown to disrupt the 
RhoA/focal adhesion kinase (FAK)/Akt signaling pathway in highly invasive 
breast cancer cells [254]. Finally, Statin can block tumor necrosis factor-α (TNF-α) 
induced expression of E-selectin on endothelial cells, effectively blocking the 
attachment of tumor cells to the endothelium [255].  
 
1.5 Hypothesis and Objectives of Our Study 
 
 
Study done by our group have recently unraveled DDX20 as a crucial 
player in the metastasis of breast cancers, where DDX20 increases the 
invasiveness of breast cancers through activation of Iκκ complex, leading to 
activation of NF-κB and its downstream targets MMP9 and CXCR4 (Hay and 
Shin et. al., manuscript under revision). Our initial screenings on a series of 
normal and breast cancer cell lines demonstrated that DDX20 is overexpressed 
specifically in invasive/metastatic breast cancer cell lines. This is further 
confirmed by preliminary data from immunohistochemistry staining of patients‟ 
tumor tissues, where DDX20 is also shown to be upregulated in metastatic breast 
cancers. This discovery makes DDX20 a potential therapeutic marker in invasive 
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breast cancers. Recently, we have further uncovered the potential to target 
DDX20 by Statin, a drug commonly used for treating hypercholesterolaemia. 
 
 
This has prompted us to study the mechanism with which Statin 
downregulate DDX20. Recent reports have uncovered miRNAs as new players in 
the regulation of lipid metabolism. Therefore, we hypothesize that Statin can 
downregulate DDX20 via 1) the canonical MVA pathway and 2) non-canonical 
pathway through miRNAs. We seek to further characterize these two pathways 
and the possible events leading to the inhibition of NF-κB and the abrogation of 
metastasis.  
 
The project is divided into three areas as follows, where the first part is 
focused at evaluating the involvement of MVA pathway, and the second part on 
the discovery of miRNAs through which statin exert its effects (summarized in 
Figure C): 
 
Aim 1: To assess the effect of Statin-mediated DDX20 downregulation.  
 
Aim 2: To investigate if the Statin-induced DDX20 is mediated through the 
canonical MVA pathway.  
 
Aim 3: To investigate investigate if the Statin-induced DDX20 is mediated  





















Figure C. Summary of project. Statin might downregulate DDX20 through 
canonical MVA pathway and non-canonical pathway via miRNAs. Solid red 
arrows represent pathways that are known, while dashed red arrows represent 





CHAPTER 2: MATERIALS AND METHODS  
 
2.1 Cell lines and cell culture  
The human mammary carcinoma cell lines, BT-549, MCF-10A, MCF-7 and 
MDA-MB-231 were obtained from American Type Culture Collection (Manassas, 
VA, USA). MDA-MB-231 cell line overexpressing Empty Vector (EV) and 
DDX20 (OE) were generated by Dr. Eun Myoung Shin.  MCF-10A cells were 
cultured in MEGM™ Mammary Epithelial Cell Growth Medium (Lonza) with 10% 
heat-inactivated Fetal Bovine Serum (FBS, Hyclone, Irvine, CA, USA), were 
cultured in Roswell Park Memorial Institute 1640 medium (RPMI, Hyclone, 
Logan, Utah, USA)  with 10% heat-inactivated fetal bovine serum, 1% L-
glutamine, and 1% penicillin/streptomycin (Hyclone, ThermoScientific, Waltham, 
MA, USA).  MDA-MB-23, EV and OE cells were cultured in Dulbecco‟s 
Modified Eagle‟s Medium (DMEM, Hyclone, Logan, Utah, USA) supplemented 
with 10% heat-inactivated fetal bovine serum, 100IU/ml penicillin, 100μg/ml 
streptomycin, and 2mM L-glutamine.  All cells were cultured at 37°C in a 





















The plasmids pcDNA3.1 and pcDNA-DDX20 were generous gifts from Dr 
Martin Lee (National University Hospital, Singapore). Lentiviral construct 
pBOBI-DDX20 was cloned by Dr. Eun Myoung Shin.  
 
The rest of the oligonucleotides used in the transfection studies are listed below.  
 
Table 2.1 List of short oligonucleotides used in transfection   
 
Oligo name Commercial name Catalogue 
number 
Company 
Control SiRNA AllStars Negative   
Control siRNA 
1027281 Qiagen 
SiDDX20 Stealth RNAi™ 
siRNA 









AM17110  Life Technologies, 
USA 
Precursor miR-










Anti-miR-ctrl miRCURY LNA™ 
microRNA Antisense 
Control A 
199004-00 Exiqon, Denmark 
Anti-miR-222 miRCURY LNA™ 
microRNA inhibitor  
 (hsa-miR-222) 






2.3 Total RNA extraction 
 
Total RNA including low molecular weight (LMW) RNAs were extracted with 
mirVana
TM
  microRNA Isolation Kit (Life Technologies, USA) following 
manufacturer‟s instructions. Briefly, 1x106 cells were lysed in 500 μl of lysis 
buffer and 50 μl of miRNA homogenate additive and incubated on ice for 10 
minutes. The lysate were then mixed with 600μl acid-phenol and centrifuged at 
13,000 rpm for 5 minutes. The top-layer of the lysate were carefully collected and 
mixed with 100% ethanol and passed through collection columns. The columns 
were washed once with 600 μl of Wash Buffer 1, twice with 500 μl Wash Buffer 
2/3 and once with 700 μl of 80% ethanol in nuclease free water, by centrifuging 
briefly at 10,000 rpm. The columns were then dried by centrifuging at 11,000 rpm 
for an additional minute and the total RNA including LMW RNAs were then 
eluted with 50μl of nuclease free water preheated at 99°C. 
 
 
2.4 Reverse transcription quantitative polymerase chain reaction (RT qPCR) 
 
 
The expression of specific miRNAs identified to be significantly differentially 
expressed in HCC was validated with Taqman-based RT-qPCR using Taqman 
MicroRNA Individual Assays (Table 2.2). RNA concentration was measured and 
reverse transcription reaction was carried out on 200 ng of template total RNA 
with the Taqman MicroRNA Reverse Transcription Kit (Life Technologies, USA) 
and the respective miRNA specific reverse transcription primers (Life 
Technologies, USA). The reaction mixture was incubated at 16 °C for 20 minutes 
for primer annealing and this was followed by reverse transcription at 42 °C for 
one hour, deactivation at 85 °C for 5 minutes and pause at 25 °C. Real-time PCR 
was performed in a 10 μl reaction mix comprising 2 μl of 5X diluted reverse 
transcription product, 5 μl of Taqman 2X Universal PCR Master Mix without 
UNG Amperase, 1 μl of miRNA specific probes and primers and 1 μl of nuclease 
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free water, on an Applied Biosystems 7500 Real Time PCR system, with an initial 
denaturation step at 95 °C for 10 minutes, followed by 40 cycles of 95 °C for 15 
seconds and 60 °C for 1 minute. Fluorescence signal was measured at each 
extension step. The level of transcript expression was measured by threshold 
cycle (CT), which was determined as the fractional cycle number at which the 
fluorescence intensity exceeded a fixed threshold, and the ΔΔCT method was 
employed for relative quantitation of gene expression [252]. The normalized CT 
(ΔCT) was calculated by subtracting the CT of an endogenous control from the 
CT of gene of interest. The ΔΔCT was calculated by subtracting the ΔCT of the 
control sample from that of the treated samples. The fold change was calculated 
with the equation 2-ΔΔCT. 
 
 
Table 2.2 List of Taqman microRNA individual assays 
 
 




















2.5.1 Transfection of small-interfering (siRNA) or miRNA precursors or 
miRNA inhibitors  
 
MDA-MB-231 cells were seeded into 6 well plates or 100mm tissue culture 
dishes and grown to 60% confluency. Lipofectamine® RNAiMAX Transfection 
Reagent (Invitrogen, Life Technologies) was used to transfect small 
oligonucleotides such as Control Oligonucleotides, miRNA precursors and 
miRNA inhibitors in according to manufacturer‟s recommendations. Table 2.9 
listed the small oligonucleotides used in this study. Briefly, for every reaction, 5 
μl of Lipofectamine® RNAiMAX Transfection Reagent and stock 
oligonucleotides were mixed respectively in 250 μl of OptiMEM medium 
(Invitrogen, Life Technologies) and incubated at room temperature for 5 minutes. 
After that, the transfection reagent and stock oligonucleotides were mixed and 
incubated at room temperature for 30 mins. This reaction mixture was then added 
into individual wells containing 1.5 ml of normal growth medium each and 
incubated overnight. After 16 hours incubation, the cells were washed with PBS 
and incubated with DMEM for 24 to 48 hours and harvested.  
 
2.5.2 Transfection of plasmid DNA  
 
MDA-MB-231 cells were seeded into plates and dishes and grown to 70% 
confluency. Plasmid DNA was diluted in 200μl JetPRIMETM buffer (Polyplus-
transfection Inc, NY, USA), vortexed for 10 seconds. 2μl JetPRIMETM (Polyplus-
transfection Inc, NY, USA) was added to the mixture, vortexed and left to 
incubate for 10 minutes at room temperature. The reaction mixture was added into 






2.6 Colony forming assay  
 
EV and OE cells were seeded in 6-well tissue culture plates and treated with 
simvastatin for 18 hours. The cells were then trypsinized and re-plated. 
Approximately 10,000 EV and OE cells were seeded on 100mm tissue culture 
dishes. After 14 days, cells were stained with 0.1% crystal violet. The amount of 
the colonies in each dish was calculated. The data were presented as the average 
from two independent experiments. 
 
2.7 Soft-agar assay 
 
Each well of a 24-well plate was covered with a base agar layer of 0.5% agarose 
in serum free DMEM media. Dissolved DNA grade agarose at 0.5% (400μl/well 
of 24 well plate) was added and left to set at 37°C for 30 minutes. DNA grade 
agarose (0.7%) was prepared in serum free culture media and incubated in a water 
bath set at 42ºC to maintain cellular viability and to avoid polymerisation of the 
agarose. An equal amount of serum free culture media was also warmed up to 
42ºC. Cells were trypsinized, resuspended in complete media and pipetted up and 
down approximately 30 times to ensure a single cell suspension. 5 x 10
3 
cells were 
resuspended in serum free DMEM and warm 0.7% agarose via pipetting. This 
mixture (0.35% agarose) was added to each well on top of the base agarose. All 
plates were left at 37°C for 1h to allow agarose to set and 400μl of DMEM 
complete media with 10μM simvastatin was then added to each well. The media 
was changed every third day for 14 days. At day 14, the media was drained and 
then all wells were washed three times with 1X PBS for 5 min. Pictures and 








2.8 Annexin V/PI binding assay  
 
Apoptosis was measured using flow cytometry to quantify the levels of detectable 
phosphotidylserine on the outer membrane of apoptotic cells. Briefly, 
5 × 10
5
 cells were exposed to 10μM Simvastatin for 24 hours. Subsequently, cells 
were trypsinized, both floating and attached cells were collected, washed with 
PBS and re-suspended in a 200 μl binding buffer solution (10 mM HEPES–NaOH, 
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). Then, 4 μl of Annexin V–FITC antibody 
(BD Pharmingen, San Diego, CA, USA) was added and further incubated in the 
dark for 30 minutes. After that, 2 μl PI solution (Sigma-Aldrich, St Louis, MO, 
USA) was added and and the cells were analyzed immediately by flow cytometry 
LSR II (BD Biosciences, San Jose, USA) using FACS Diva software 7.0 (BD 
Biosciences, San Jose, USA). For each sample, the fluorescence of 10,000 cells 
was collected and counted. The percentage of cells in the lower left (Annexin 
V/PI double negative, viable), lower right (Annexin V positive/PI negative, early 
apoptotic), upper right (Annexin V positive/PI positive, late apoptotic cells) and 
upper left (Annexin V negative/PI positive, necrotic cells) portion of the 
histogram was calculated for comparison. 
2.9 Cell cycle analysis 
 
The cells were grown at a density of 0.5 × 10
6
 cells in 6-well tissue culture plates 
and then treated with 10μM simvastatin for 24 hours. The cells were trypsinized, 
washed twice with cold PBS and centrifuged. The cell pellet was re-suspended in 
100μl cold PBS and then fixed in 1 ml 75% ice- cold ethanol for at least 1 hour. 
After the fixation, wells were centrifuged at 10,000 rpm for 5 minutes and then 
washed with cold PBS. Cells were then resuspended in 500μl PBS containing 
ribonuclease (10μg/ml) and PI solution (10μg/ml) and incubated at 37 °C for 
30 minutes. The data were acquired and analyzed on flow cell cytometer using 




2.10 Luciferase assay 
 
 
MDA-MB-231 cells were plated in 12-well plates and transfected with luciferase 
reporter plasmid containing NF-κB luciferase repoter gene constructs together 
with Renilla plasmid (pRL-TK) (Clontech, CA, USA).  Cells were treated with 
simvastatin 24 hours post-transfection. The promoter activity was assessed 24 
hours post-treatment with a dual luciferase assay kit (Promega, WI, USA). Briefly, 
cells were scarped and lysed in 100μl lysis buffer at -80°C for at least 1 hour. The 
lysate was then centrifuged at 13,000rpm for 15 minutes. 10μl of lysate was added 
to 50μl luciferase substrate solution and the luminescence generated was read 
using a Sirius luminometer (Berthold Technologies, Herefordshire, UK). 50μl 
stop & glow buffer was added immediately after the first reading to measure 
Renilla activity. The luminescence readings normalized to the protein 
concentration of the corresponding cell lysate and presented as fold difference 
with reference to the control setup.  
 
 
2.11 Western blotting analysis  
 
Cells were scraped and lysed with RIPA lysis buffer (150 mM NaCl, 50 mM Tris-
HCl pH 7.0, 1% Deoxycholate, 1% NP40, 0.1% SDS) supplemented with 
protease inhibitor cocktail (Roche, Germany) on ice for 15 minutes and 
centrifuged at 13,000 rpm for 15 minutes to collect total cell lysate. Concentration 
of protein was measured with Coomassie Plus Kit (Pierce, IL, USA) and 
absorbance was read at 595nm using a Spectrofluoro Plus spectrophotometer 
(TECAN, GmbH, Austria). Protein standards were prepared using bovine serum 
album (Peirce, IL, USA). Based on the absorbances of standards, the standard 
curve was plotted, and the absorbance of the unknown protein sample was 
calculated from the standard curve. For detection of protein expressions, 40μg of 
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protein lysates were resolved on a 10 % SDS-PAGE gel at 80V for 15 minutes 
followed by 100V for 100 minutes using Bio-Rad Mini-PROTEAN 3 Cell (Bio-
Rad Laboratories, CA, USA) and transferred onto a nitrocellulose membrane (Pall 
Corporation, USA) at 100V for 90 minutes. The blots were blocked with 5% fat-
free milk in Tris-buffered saline/0.1% (v/v) Tween-20 (TBS-T) for 1 hour and 
probed respective primary antibody and horseradish peroxidase conjugated 
secondary antibody. The primary and secondary antibodies were diluted as 
indicated in Table 2.2. The blots were then washed and visualized with 



























CHAPTER 3: RESULTS 
 
3.1 Statin induce DDX20 downregulation in triple-negative breast cancer cell 
lines  
 
3.1.1 DDX20 is downregulated by Statin in triple-negative breast cancer cell 
lines.  
Previous studies from our lab have shown that DDX20 is overexpressed in 
invasive breast cancer cell lines. The next step is to look at how DDX20 can be 
exploited as a therapeutic target using Statin. As Statin treatment abrogates NF-
κB signaling, I reason that DDX20 could also be a potential target of Statin. Two 
triple-negative breast cancer cell lines, MDA-MB-231 and BT-549, were selected 
for the study. Both cell lines were treated with 1μM, 5μM and 10μM simvastatin 
and lovastatin respectively for 24 hours. Our first screening revealed that Statin 
can induce DDX20 downregulation at the mRNA and protein level (Figure 3.1.1) 
in these cells in a dose-dependent manner.  
 
3.1.2 DDX20 is a potential therapeutic target for Statin treatment.  
 
Next, I went on to check if the manipulation of DDX20 can reverse or 
rescue the effects of Statin. Empty vector (EV) and DDX20 overexpressing (OE) 
cells were treated with 10μM of simvastatin and re-plated in low density to allow 
for colony formation. The colonies were then stained with 0.1% crystal violet and 
counted. There were no significant differences between the number of colonies 
formed from the EV and OE cells (Figure 3.1.2A). The anchorage-independent 
growth of the cells was also measured by soft agar assay. Both EV and OE cells 
formed big colonies, but interestingly, in comparison to EV cells, OE cells 
aggregated, formed many more and bigger colonies and protrusions. Upon 
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simvastatin treatment, EV colonies shrunk and died but OE colonies are more 
resistant to simvastatin treatment (Figure 3.1.2B).  
 
Apoptotic profiles of Statin-induced cell death were also assessed in both 
EV and OE cells by quantifying the levels of detectable phosphotidylserine on the 
outer membrane of apoptotic cells using Annexin V/PI binding assay. Both cell 
lines were treated with 10μM simvastatin for 48 hours and analyzed on a flow 
cytometer. For EV cells, only 23.75% of cells were viable, indicated by Annexin 
V and PI double negative staining, while for OE cells, it was 36.71% (Figure 
3.1.3A). When the protein levels of DDX20 in these cells were assessed by 
western blotting, I found that DDX20 was not downregulated in OE cells in 
comparison to EV cells (Figure 3.1.3B, lane 4). In order to check if the 
overexpression of DDX20 affects the MVA pathway, I also assessed the levels of 
HMGCR. I showed that the expression of HMGCR was upregulated in 
simvastatin-treated EV cells (Figure 3.1.3B, lane 2) but not OE cells (Figure 
3.1.3B, lane 4). 
 
As the overexpression of DDX20 did not seem to give consistent results, 
possibly due to the saturation of levels of DDX20 in the cell line, I went on to 
look at the effects of the knock-down of DDX20. Silencing of DDX20 has a 
profound effect on the colony forming ability of the cells. As show in Figure 3.1.4, 
silencing of DDX20 increased the sensitivity of cells to simvastatin treatment, 
further reducing the number of colonies formed in comparison to simvastatin-
treated cells that were transfected with control siRNA. On the other hand, when 
the treated cells were assessed by cell cycle analysis, it was consistent with other 
observations that simvastatin can induce sub-G1 cell cycle arrest in MDA-MB-
231 cells [256, 257]. Simvastatin-treated control-transfected cells (31.8%) and 
silencing of DDX20 (34.13%) both induced sub-G1 arrest (Figure 3.1.5) but there 







Figure 3.1.1. Statin induces DDX20 downregulation in triple- negative breast 
cancer cell lines.  MDA-MB-231 and BT-549 triple negative breast cancer cell 
lines are treated with 1μM, 5μM and 10μM simvastatin and lovastatin 
respectively for 24 hours. The mRNA (A) and protein (B) levels of DDX20 were 
assessed by qRT-PCR and Western Blotting. Both the transcript and protein levels 












Figure 3.1.2. Overexpression of DDX20 does not significantly affect 
anchorage-dependent growth but attenuates Statin-mediated anti-anchorage 
independent growth. (A) EV and OE cells were treated with 10μM simvastatin 
for 24 hours and re-plated at a low density to allow for colony formation. After 14 
days, cells were stained with 0.1% crystal violet and counted. (B) Empty vector 
(EV, Top panel) and DDX20-overexpressing (OE, Bottom panel) breast cancer 
cells were seeded in Matrigel coated wells and were subsequently treated with 
either 5μM or 10μM of simvastatin for 14 days. Both untreated EV and OE cells 
formed huge colonies although OE cells aggregated into bigger colonies (black 
arrow-heads). Cells formed growing protrusions (black arrows) in the matrigel, 
Both EV and OE cells were treated with either 5μM or 10μM simvastatin. Treated 













Figure 3.1.3. Overexpression of DDX20 does not affect Statin-induced cell 
death. (A) EV and OE cells were treated 10μM simvastatin for 48 hours and 
analyzed by flow cytometry. Relative apoptosis (total apoptotic cells) and relative 
cell death (total apoptotic plus total necrotic cells) were computed based on 
results generated from flow cytometry. (B) The protein levels of DDX20 were 










Figure 3.1.4. Silencing of DDX20 decreases the colony forming ability 
(anchorage-dependent growth) of cells. MDA-MB-231 cells were transfected 
with control siRNA and si-DDX20 respectively. Cells were treated with 10μM 
simvastatin for 24 hours, re-plated at a low density and allow for colony 
formation for 12 days. Colonies were stained with 0.1% crystal violet. Inner box 
shows the western blot analysis of expression of DDX20 in control-treated and si-






















SubG1 10.67 48.28 11.60 43.27 
G1/S 53.37 31.80 50.00 34.13 
S 16.29 7.28 18.00 9.62 
G2/M 19.66 12.64 20.40 12.98 
 
Figure 3.1.5. Silencing of DDX20 does not increase the sensitivity of cells to 
Statin-induced sub-G1 arrest. MDA-MB-231 cells were transfected with 
control siRNA and si-DDX20 respectively. Equal number of cells was re-plated 
48 hours after transfection, treated with 10μM simvastatin for 24 hours and 
harvested for cell cycle analysis. Top panel shows the histogram analysis of the 








3.2 Statin-induced DDX20 downregulation is mediated through the canonical 
MVA pathway 
 
3.2.1 MVA rescues Statin-induced DDX20 downregulation.  
 
Statin inhibit the rate-limiting enzyme of MVA pathway, i.e. HMG-CoA 
reductase. Hence, in order to confirm that Statin-mediated DDX20 
downregulation is mediated through the inhibition of MVA pathway, rescue 
experiments were performed. MDA-MB-231 cells were pre-incubated with or 
without 100μM MVA, followed by 10μM Simvastatin treatment. Simvastatin-
induced DDX20 downregulation is abrogated when cells are pre-incubated with 
100μM MVA (Figure 3.2.1), both at the mRNA (Top panel) and protein level 
(Bottom panel). This rescue confirms that the Statin-induced DDX20 
downregulation is mediated through MVA pathway.  
 
3.2.2 Statin-induced DDX20 downregulation is via the GGPP pathway. 
 
The MVA pathway produces many metabolites and end-products which 
are important for many cellular functions. Isoprene units incorporated into 
compounds such as GGPP and FPP are important for synthesis of cholesterol and 
prenylation of Ras and many small GTPases such as Rac, Rho and cdc-42. In 
order to further dissect the pathway through which Statin downregulate DDX20, 
MDA-MD-231 cells were pre-incubated with 10μM FPP or GGPP for at least two 
hours before treatment with 5μM simvastatin. Pre-incubation with GGPP but not 
FPP rescued the downregulation of DDX20 at the mRNA and protein levels 
(Figure 3.2.2A and B respectively). This suggests that Statin-induced DDX20 
downregulation is mediated through the GGPP pathway. While FPP originally 
lies upstream of GGPP in the MVA pathway, the addition of FPP cannot rescue 
Statin-induced DDX20 downregulation because a second metabolite needed for 
conversation of FPP to GGPP, Isopentenyl PPi, is also depleted by exposure of 
cells to Statin.    
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3.2.3 Treatment of cells with GGTI recapitulates Statin-mediated effects in 
MDA-MB-231.  
 
Analogues of FPP and GPP, i.e. FTI and GGTI respectively, can compete with 
FPP and GGPP for farnesyl transferase and geranylgeranyl transferase. Addition 
of FTI did not cause a downregulation in DDX20, but addition of 5μM and 10μM 
GGTI mimicked the effects of Statin and induced DDX20 downregulation. This 
confirmed that the effect of Statin-induced DDX20 in invasive breast cancer cells 
















Figure 3.2.1. MVA rescues Statin-induced DDX20 downregulation. (A) 
MDA-MB-231 cells were pre-incubated with or without 100μM MVA for 2 hours 
before addition of 10μM Simvastatin. The mRNA (top panel) and protein (bottom 
panel) levels of DDX20 were assessed 24 hours after treatment. (B) Morphology 














Figure 3.2.2. GGPP rescues the effect of Statin. (A and B) MDA-MB-231 cells 
were pre-treated with 10μM GGPP or FPP before treatment with 10μM 
simvastatin. The mRNA (A) and protein (B) level of DDX20 was assessed after 
treatment. Data is presented as average mRNA fold changes ± SEM, n = 3 
experiments (*, p<0.05).  
 
Figure 3.2.3. Treatment of cells with GGTI recapitulates Statin-mediated 
effects in MDA-MB-231.  (A and B) MDA-MB-231 were pre-incubated with 
5μM and 10μM GGTI or FTI for 24 hours. The mRNA (A) and protein (B) levels 
of DDX20 were assessed 24 hours after treatment. Data is presented as average 
mRNA fold changes ± SEM, n = 3 experiments (*, p<0.05).  
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3.2.4 Silencing of DDX20 abrogates NF-κB signaling.  
 
Our previous study (Hay and Shin et al., under revision) showed that 
under genotoxic stress, DDX20 is essential for the SUMOylation of NEMO, 
leading to the activation of NF-κB and hence MMP9, which is frequently 
activated and overexpressed in invasive breast cancers. Studies have also shown 
that Statin can reduce the DNA-binding ability of NF-κB through EMSA and 
supershift assays signaling, and this effect is mediated through MVA pathway, 
but the exact mechanism through which Statin abrogate NF-κB signaling in 
invasive breast cancers still remains unknown.  
 
I transfected MDA-MB-231 cells with control siRNA and si-DDX20, 
treated the transfected cells with 10μM simvastatin and measured the luciferase 
activity using an NF-κB luciferase reporter assay. The promoter activity of NF-κB 
went down 6 hours post-treatment for control transfected cells, but the promoter 
activity was attenuated as early as 3 hours post-treatment for si-DDX20 
transfected cells (Figure 3.2.4). Thus far, others have reported the Statin-induced 




















Figure 3.2.4. Silencing of DDX20 abrogates NF-κB signaling. MDA-MB-231 
cells were transfected with control siRNA or si-DDX20 and an NF-κB luciferase 
reporter plasmid. The cells were then treated with 10μM simvastatin for the time-
points indicated in the graphs and harvested for luciferase assay. Data is presented 



















3.3 Statin-induced DDX20 downregulation can also be mediated through the 
non-canonical miRNA-regulated pathway 
 
3.3.1 In silico analysis of the 3’-UTR of DDX20 showed that DDX20 can be 
regulated by miRNAs.   
 
Recent studies have reported the  miRNAs as new players in the regulation 
of lipid metabolism The 3‟-UTR of DDX20 was analysed by in silico prediction 
algorithms miRanda (August 2010 Release) and TargetScan Human (Release 6.2), 
two of the most widely-used algorithms which provide sufficient coverage and 
stringent selection criteria. Shown here (Figure 3.3.1) are screen captures of the 
analysis from miRanda and TargetScan, where the alignment of the seed 
sequences of the respective miRNAs and the target regions were depicted. The 
overlapped candidates were then selected for further analysis. MiR-125a-5p/125b, 
miR-221/222, miR-641 and miR-655 were among the selected candidate miRNAs 
that were predicted to regulate DDX20. Mir-125a-5p/125b and miR-221/222 were 
selected because they were shown to be involved in breast cancer progression. 
MiR-641 and miR-655 were selected because they were novel miRNAs that were 









Figure 3.3.1. Representative screen captures of the analysis of 3’-UTR of 
DDX20. The 3‟-UTR of DDX20 is analysed by MiRanda (August 2010 Release, 
top panel) and TargetScan (bottom panel), two online prediction algorithms. The 
figures showed a detailed screen capture of the online softwares used, and the 
alignment between the 3‟-UTR of DDX20 and the respective miRNAs. From the 
top to bottom, alignment between the 3‟-UTR of DDX20 and miR-222, miR-
125a-5p, miR-125b, miR-641 and miR-655.  
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3.3.2 Basal expression of candidate miRNAs in breast cancer cell lines.   
 
The expression levels of the respective candidate miRNAs were then 
evaluated in a panel of normal breast epithelial and breast cancer cell lines. The 
cell lines selected for the initial screening include 184A1 (normal breast epithelial 
cell), MCF7, T47D, BT-474, Sk-Br3, BT-549 and MDA-MB-231, arranged in the 
order of their invasiveness. The expression level of miR-125a was slightly higher 
in Her-2 positive cell lines (BT-474 and Sk-Br3) while miR-125b was 
overexpressed in invasive breast cancer cell lines (BT-549 and MDA-MB-231). 
Consistent with published data, both miR-221 and miR-222 were overexpressed 
in ER-α negative cell lines (BT-549 and MDA-MB-231) and Her-2 positive cell 
lines but not in ER-α positive cell lines (MCF7 and T47D).  Both miR-125b and 
miR-222 were selected for downstream studies as they are highly expressed in 
invasive breast cancer cells. The expression level of miR-641 and miR-655 were 
very low and undetectable in some cell lines, as such, they will not be selected for 
future studies (Figure 3.3.2).  
 
3.3.3 Manipulation of miR-125b and miR-222 showed that only miR-222 is a 
possible regulator of DDX20.  
 
The expression levels of miR-125b and miR-222 were manipulated by 
overexpressing the miRNAs using their respective miRNA precursors (synthetic 
miRNA mimics) and silencing the miRNAs using anti-miR miRNA inhibitors. As 
shown in Figure 3.3.3, both overexpression and silencing of miR-125b 
upregulated the level of DDX20, which suggested that the upregulation of 
DDX20 in this case was a possible off-target effect. On the other hand, miR-222 
was overexpressed in MCF-7, which has a low level of miR-222 while it was 
silenced in MDA-MB-231 which has a higher level of miR-222. Overexpression 
of miR-222 in MCF-7 resulted in the downregulation of DDX20 while the 
silencing of miR-222 in MDA-MB-231 led to the upregulation of DDX20. The 
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opposite effects observed suggest that miR-222 could be a potential miRNA 




Figure 3.3.2. Basal expression of candidate miRNAs in panel of breast cancer 
cell lines.  The expression levels of miR-125-a/125b (top row), miR-221/ -222 
(middle row), miR-641 (bottom left) and miR-655 (bottom right) were assessed 
by RT-qPCR in a panel of breast cancer cell lines. The cell lines were arranged in 
the magnitude of their invasiveness, where 184A1 is a normal breast epithelial 
cell lines, MCF7 and T47D are both ER-α positive cell lines that are non-invasive, 
BT-474 and SkBr3 are Her-2 positive cell lines that are weakly invasive, while 









Figure 3.3.3. Manipulation of miR-125b showed off-target effects. miR-125b 
were overexpressed (A) and silenced (B) in MDA-MB-231 cells. The expression 
of DDX20 was assessed by real-time qPCR. The expression of DDX20 was 
upregulated in both the overexpression and silencing of miR-125b. Control used 
for (A) and (B) were a scrambled miRNA Antisense Control A and Pre-miR
TM 




















Figure 3.3.4. The effects of manipulation of miR-222 on DDX20. (A) miR-222 
was overexpressed (A) by transfecting MCF7 cells with 10nM, 20nM and 50nM 
of miRNA precursors. The expressions of both miR-222 (top panel) and DDX20 
(bottom panel) were assessed by real-time qPCR. (B) miR-222 was silenced by 
transfecting MDA-MB-231 cells with 25nM, 50nM and 100nM of anti-miR-222 
miRNA inhibitors. The expressions of both miR-222 (top panel) and DDX20 
(bottom panel) were assessed by real-time qPCR. Data is presented as average 













3.3.4 MiR-222 was upregulated upon Statin treatment in triple-negative 
breast cancer cell lines.  
 
In order to test the hypothesis that Statin can downregulate DDX20 
through the non-canonical pathway via miRNA, the expression of miR-222 was 
assessed by qRT-PCR. miR-222 was selected because it was predicted to be a 
miRNA regulator of DDX20. While manipulation of miR-222 did not affect 
DDX20, I reasoned that it is still possible that miR-222 could be induced to target 
DDX20 under different physiological conditions. As I was working on Statin in 
parallel, it was a possibility that miR-222 could be induced by Statin since miR-
222‟s expression could be affected by many drugs as described in introduction. 
As shown in Figure 3.3.5, DDX20 was downregulated in both MDA-MB-231 and 
BT-549 cell treated with simvastatin in a time-dependent manner. Interestingly, 
miR-222 exhibited the opposite trend, but also in a time-dependent manner 
(Figure 3.3.5). This supported the hypothesis that a non-canonical pathway is 
plausible; miR-222 could mediate DDX20 downregulation upon Statin treatment 
in triple negative breast cancer cell lines. I also assessed the expression of miR-
221 since it is a family member of miR-222. Intriguingly, I did not observe a 
consistent trend on the expression of miR-221 (family member of miR-222) upon 
simvastatin treatment (Figure 3.3.6).  
 
3.3.5 Manipulation of miR-222 did not rescue or aggravate Statin-induced 
DDX20 downregulation.  
 
I reason that if the Statin-induced DDX20 downregulation was regulated 
by miR-222, manipulation of level of miR-222 will probably affect this 
observation.  Knock-down of miR-222 did not rescue the Statin-induced 
downregulation of DDX20. On the same token, overexpression of miR-222 
(Figure) did not result in a further downregulation of DDX20 upon Statin 
treatment (Figure 3.3.7). This implied that 1) miR-222 is responsible for other 
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targets involved in Statin pathway, and 2) Statin-induced DDX20 downregulation 
might be regulated by other miRNAs. Interestingly, when the expression of miR-
222 was manipulated, I noted that there was a tendency for the cells to upregulate 
miR-222 upon Statin treatment. This implied that miR-222 is important for the 



















Figure 3.3.5. miR-222 is upregulated upon Statin treatment. MDA-MB-231 
and BT-549 cells were treated with 10μM simvastatin for 6, 12, 18 and 24 hours. 
The expression of miR-222 was assessed by qRT-PCR. MiR-222 was upregulated 
in MBA-MD-231 (A) and BT549 (B) in a time-dependent manner. Data is 




Figure 3.3.6. Statin treatment does not upregulate miR-221. MDA-MB-231 
and BT-549 cells were treated with 10μM simvastatin for 6, 12, 18 and 24 hours. 
The expression of miR-221 was assessed by qRT-PCR. MiR-222 was upregulated 
in MBA-MD-231 (A) and BT549 (B) in a time-dependent manner Statin 
treatment do not show a consistent upregulation in MDA-MB-231 (A) and BT549 






Figure 3.3.7. Manipulation in the expression of miR-222 does not affect 
Statin-induced DDX20 downregulation. (A) MDA-MB-231 cells were 
transfected with precursors-miR-222 (mimics) or anti-miR-222 inhibitors. 
Transfected cells were subsequently treated with 10μM simvastatin for 24 hours 
and harvested for Western Blotting analysis. (B) The expression of miRNA was 
quantified by qRT-PCR in cells transfected with precursor-222 and anti-miR-222 
inhibitors to show the overexpression and knocked down of miR-222 (UT, 
























Figure 3.3.8. Forced upregulation of miR-222 upon Statin treatment. The 
expression of miR-222 was knocked down (top panel) and overexpressed (bottom 
panel) in MDA-MB-231 cells. The cells were treated with 10uM simvastatin and 
the expression of miR-222 was assessed by real-time PCR. As shown in top panel, 
in miR-222 knock-down samples, miR-222 was forcibly upregulated upon 
simvastatin treatment. Statin treatment also resulted in further upregulation of 
miR-222 in precursor miR-222 overexpressing cells (bottom panel). Data is 





3.3.6 Manipulation of miR-222 affected Statin-induced apoptosis. 
 
For the first time, I found that miR-222 is upregulated in Statin treatment 
cells. I reason that the upregulation of miR-222 could be pivotal for one of the 
Statin-induced effects, most prominently, apoptosis. I overexpressed precursors of 
miR-222 and knocked down miR-222 in MDA-MB-231 cells to assess the effects 
on Statin-induced apoptosis using Annexin V/PI binding assay. Interestingly, I 
found that knocking down miR-222 protected the cells from Statin-induced cell 
death (Figure 3.3.10) while overexpressing miR-222 sensitizes cells to Statin-
induced cell death (Figure 3.3.11).  
 
As the manipulation of miR-222 led to changes in the sensitivity of cells 
in Statin-induced apoptosis, it is tempting to speculate that miR-222 might be 
targeting some apoptotic-related genes. I utilized miRecords 
(http://mirecords.biolead.org), a database which collects records from all in silico 
predictions algorithms for validated and predicted miRNAs‟ targets. According to 
miRecords, miR-222 could be a potential regulator of a large number of apoptotic 
genes, such as the anti-apoptotic Bcl-2 and Bcl-xl (Figure 3.3.12).  
 
Subsequently, I decided to look at the expression of some anti-apoptotic 
and pro-apoptotic genes in the same set-up of experiments. I showed that cleaved 
Caspase-3 was upregulated in simvastatin-treated precursor-222 overexpressing 
cells in comparison to miR-222 knock-down samples (Figure 3.1.13A, Right 
panel, lane 3). In fact, without simvastatin treatment, miR-222 knocked-down 
cells had lesser cleaved Caspase-3 (Figure 3.1.13A, left panel, lane 2) while cells 
overexpressing miR-222 had the tendency to upregulate cleaved Caspase-3 
(Figure 3.1.13A, right panel, lane 2). Remarkably, I also demonstrated that Bcl-2 
was downregulated in cells overexpressing miR-222 (Figure 3.1.13B, lane 4) but 







Figure 3.3.9. Knock-down of miR-222 protects cells from Statin-induced 
apoptosis. (A) miR-222 was knocked down in MDA-MB-231 cells and treated 
with 10uM simvastatin for 24 hours. Subsequently, cells were stained with 
Annexin V-FITC antibody and PI solution and the apoptotic profiles of cells were 
assessed by flow cytometry. (B) The relative apoptosis (left panel) and relative 
cell death (middle panel) were computed based on the results of flow cytometry 
(see Materials and Methods) (***, p< 0.001). Right panel shows the 






Figure 3.3.10. Overexpression of miR-222 sensitizes cells to Statin-induced 
apoptosis. (A) miR-222 was overexpressed in MDA-MB-231 cells and treated 
with 10uM simvastatin for 24 hours. Subsequently, cells were stained with 
Annexin V-FITC antibody and PI solution and the apoptotic profiles of cells were 
assessed by flow cytometry. (B) The relative apoptosis (left panel) and relative 
cell death (middle panel) were computed based on the results of flow cytometry 
(see Materials and Methods) (**, p<0.01; ***, p< 0.001). Right panel shows the 













Figure 3.3.11. miR-222 could be a potential regulator of apoptotic genes. 
According to data collected in MiRecords (based on 11 in silico predictions 
algorithms), miR-222 could be a potential regulator of many apoptotic genes. For 
instance, based on the snapshot above, miRanda, PITA and RNAHybrid predicted 










Figure 3.3.12. miR-222 could be a potential regulator of apoptotic genes. (A) 
MDA-MB-231 cells were transfected with precursors and anti-miRNA inhibitors 
as indicated and treated with 10μM simvastatin for 24 hours followed by western 
blotting analysis of procaspase-3 and cleaved caspase-3. (B) MDA-MB-231 cells 
were transfected with precursors and anti-miRNA inhibitors as indicated and 
treated with 10μM simvastatin for 24 hours followed by western blotting analysis 

















CHAPTER 4: DISCUSSION 
 
4.1 Targeting DDX20 with Statin in vitro and beyond  
 
Earlier studies from our lab (Hay and Shin, under revision) showed that 
DDX20 is an important player in the metastasis of breast cancers, where DDX20 
increases the invasiveness of breast cancers through activation of Iκκ complex, 
leading to activation of NF-κB and its downstream targets MMP9 and CXCR4. 
Hence, there is a high possibility that DDX20 can be exploited as a therapeutic 
marker for the treatment of invasive breast cancers. Several studies have shown 
that Statin can downregulate NF-κB signaling [211, 229] in invasive breast 
cancers. Given the interaction between DDX20 and NF-κB, we reason that 
DDX20 can also be a target of Statin.  
 
My initial study showed clearly that DDX20 can be downregulated by 
simvastatin and lovastatin, the two lipophilic Statin which are commonly used in 
anti-cancer studies. Subsequently, I showed by colony forming assay that there is 
a marked difference between the control-transfected versus DDX20 silenced cells, 
which implied that silencing DDX20 can sensitize cells to Statin treatment.  
However, when the same study was repeated in DDX20 overexpressing stable 
cells, a significant difference was not observed. The stable cells that I used in the 
studies were derived from the invasive breast cancer cell line MDA-MB-231, 
which already has a high level of DDX20. The overexpression of DDX20 in this 
cell line might lead to saturation, which could attribute to the lack of differences 
in our assays. I am looking into deriving a DDX20-overexpressing cell line using 
normal breast epithelial cell line to better characterize our assays. With that, I can 
better assess the impact of the overexpression of DDX20 on Statin effects.  
 
I also noted from previous studies that a proper knock-down of at least 70% 
is needed in order to account for significant phenotypical changes, especially in 
proliferation studies. The effect of the silencing of DDX20 on proliferation is not 
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apparent in the initial stages of the knock-down studies (24 to 48 hours). This 
suggests that DDX20 might be functioning as a co-factor in certain important 
cellular processes. These processes could be crucial for survival of cells and are 
co-regulated by many other proteins, thus resulting in functional redundancy, 
which is not uncommon in many systems. This is not surprising as silencing of 
DDX20 had been shown to inhibit EBNA3C-mediated inhibition of p53-induced 
apoptosis [77]. It follows that a steady mid- to long-term depletion of DDX20 can 
overcome any possible redundancies and produces the effects that I observed. 
This is supported by our observation on DDX20-silenced cells which had poorer 
colony forming capabilities.   
 
My studies so far have only stopped at delineating the roles of DDX20 in 
Statin-induced effects on proliferation. We did show previously by invasion 
assays that Statin can inhibit the invasive capabilities of MDA-MB-231 cells and 
the overexpression of DDX20 can overcome this inhibition (Hay Hui Sin, 
Sumoylation of NEMO and NF-κB activation by a RNA helicase, DP103 defines 
the metastatic potential of human breast cancers, thesis submission 2012). 
However, as Statin can induce apoptosis and inhibit metastatic capabilities of 
cancer cells simultaneously, it is equally possible that overexpression of DDX20 
overcame this inhibition because it promoted survival. Studies are on-going to 
better characterize the relationship of the three. Pan-caspase inhibitor (zVAD-
FMK) will be used to inhibit apoptosis and then the metastatic potential of Statin-
treated cells will be investigated. The NF-κB downstream target genes, MMP9 
and CXCR4 will also be abrogated using their respective inhibitors to check for 
Statin-mediated attenuation of metastasis. The pan-caspase inhibitors, MMP9 and 








4.2 DDX20 is positively correlated to MVA-related genes  
 
  My results showed that the expression of DDX20 is crucial for Statin-
induced phenotypes. In fact, silencing of DDX20 has markedly increased the 
sensitivity of breast cancer cells to simvastatin treatment. This seems to imply that 
DDX20 can be exploited as a biomarker for Statin sensitivity in breast cancers 
which has a dysregulated MVA pathway. MVA pathway is usually dysregulated 
or constitutively activated in cancer cells, presumably because cancer cells have a 
high demand for isoprenoids and lipids for cellular processes, this could render 
them more vulnerable to the effects of Statin. Freed-Pastor and colleagues 
reported a mutant p53 which upregulated Mevalonate pathway and was correlated 
with highly expressed sterol biosynthesis genes in human breast tumors. They 
showed through 3D cultures that MVA pathway alone was enough to maintain the 
malignancy of breast cancer cells. They performed GGPP add-back experiments 
to cells that were either depleted with the mutant p53 or treated with simvastatin 
and demonstrated that addition of GGPP was sufficient to rescue the phenotype 
[258]. I showed through similar set of experiments that the downregulation of 
DDX20 can be rescued by GGPP add-back experiments. Importantly, the 
expressions of both DDX20 and HMGCR were not downregulated in the OE cells. 
Presumably, in the “normal” cells, i.e. EV cells, simvastatin treatment will lead to 
a depletion in isoprenoid intermediates and cholesterol synthesis, which will lead 
to the activation of the cytoplasmic transcription factor sterol-regulatory element 
binding protein (SREBP) feedback mechanism [210, 259, 260]. In the process, 
HMGCR will be upregulated in order to restore the cholesterol levels in the cells. 
Since HMGCR remained downregulated upon simvastatin treatment in OE cells, 
this implies that overexpression of DDX20 impairs the SREBP feedback 
mechanism. Consistent with the roles which DDX20 plays as a transcriptional 
repressor, one possibility could be that DDX20 may prevent SREBPs from 
binding to the promoter regions of their target sterol response elements (SREs), 




 Another aspect that should be looked into is the involvement of the small 
GTPases Rho, Rac and/or Cdc42 in the downregulation of DDX20. Past studies 
have demonstrated that Statin can inhibit the prenylation of the small GTPases, 
effectively blocking their translocation to the plasma membrane and activation 
[211, 218, 219]. Emerging data has revealed the importance of Rho proteins in 
carcinogenesis. Overexpressions of RhoA and RhoC have been frequently 
implicated in many cancers; RhoA is pivotal for EMT while RhoC is one of the 
major driving factors for the invasion of cancer cells. As DDX20 is required for 
metastasis, it is highly possible that RhoA actually regulates the transcription of 
DDX20. As a result, Statin-mediated RhoA downregulation will lead to the 
inhibition of DDX20. Also, other than small GTPases, many other proteins can 
also be prenylated. In this regard, it would be interesting to find out if DDX20 can 
be prenylated, and if so, whether this prenylation serves as a unique post-
translational modification that confers new roles to DDX20.  
 
4.3 Possible novel function of miR-222 in MVA pathway  
 
 Many studies have revealed that miR-221/222 family functioned as an 
oncogenic miRNA [136, 185, 261-267]. Given that they are family members with 
just a single base-pair difference in their sequences, miR-221 and miR-222 share 
many overlapping mRNA targets, such as ER-α [136, 268], Phosphatase and 
tensin homolog (PTEN) [269], tissue inhibitor of metalloproteinases-3 (TIMP3) 
[269] and p27 [270]. In the context of breast cancers, miR-221/222 also play 
many important roles, most prominently, conferring multidrug resistance [268, 
271] and promoting epithelial-mesenchymal transition (EMT) [144, 145].  
 
Here, I have uncovered a novel function of miR-222, which was not 
shared by miR-221. Unlike its oncogenic properties demonstrated thus far in 
breast cancers, I showed that knock-down of miR-222 protected the cells from 
Statin-induced cell death and overexpression of its precursor sensitizes cells to 
Statin treatment, which gave rise to the possibility that miR-222 could also 
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function as a tumor suppressor miRNA. I noted that the silencing of miR-222 
effectively reduced apoptosis but that the overexpression of miR-222 did not 
significantly affect apoptosis in comparison. One possible explanation could be 
the efficiency of the processing of the transfected oligonucleotides. For the 
silencing of miR-222, I used an miRNA inhibitor which could directly bind to the 
miRNA, but for the overexpression, it was a precursor form of the miRNA, which 
would require further processing in order to become mature miRNA that could 
carry out its functions. The real-time PCR primers used for detection for miR-222 
covers sequences which exist both in the precursor and mature form of miR-222, 
so it is hard to distinguish between the actual processed form of miR-222 from the 
precursors. If the downstream processing was not done efficiently, which 
indicated that the overexpression was not very good, then the effect might not be 
as significant.  
 
The involvement of miR-222 in apoptotic related cell death is not 
uncommon. In other cancers, for example, in primary effusion lymphoma and 
Kaposi‟s sarcoma, miR-221 and miR-222 act as tumor suppressors, controlling 
the migration of endothelial cells [272, 273]. I also noted that miRNAs are 
frequently implicated in drug resistance of cancer cells, which are nicely 
summarized by Ma and colleagues [274]. Interestingly, one study revealed that 
miR-222 regulated tamoxifen resistance of ER-α positive breast cancer cells [138]. 
Another study found that together with miR-221, miR-222 was involved in 
fulvestrant resistance through modulation of β-catenin and TGF-β-mediated 
growth inhibition [271]. Another breast cancer drug resistance study done by 
Kovalchuk and colleagues showed that transfection of MCF7/Doxorubicin-
resistant cell lines with miR-451 can increase sensitivity of cells to Doxorubicin 
by regulating the expression of the multi-drug resistance 1 (MDR1) gene [275]. In 
other cancers, for example, ectopic expression of miR-34a negatively regulates 
the resistance of colorectal cancer cells to 5‟-fluorouracil (5‟-FU) by targeting 
SIRT1 and E2F3 [276]. The famous miR-15/miR-16 cluster was also involved in 
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conferring resistance of gastric cancer cells to vincristine, doxorubicin, etoposide 
and cisplatin [277].  
 
 
Based on in silico predictions, I discovered that miR-222 could potentially 
target many anti-apoptotic genes, such as Bcl-2 and Bcl-xl, which require further 
investigations. Another possibility is that miR-222 might also be targeting 
members of the MVA pathway directly instead of apoptotic proteins. Here, I 
showed that the Statin-induced miR-222 upregulation can be rescued by addition 
of MVA, GGPP and FPP. Successful rescue by MVA add-back experiments 
suggests Statin-induced miR-222 is MVA-dependent and it is upstream of GGPP 
and FPP.  I ran a few prediction algorithms on miR-222 and HMGCR and I had 
three positive hits, but the expression of HMGCR should be assessed with an 
overexpression or silencing of miR-222. This observation also seems to imply that 
miR-222 has a direct role in cholesterol synthesis, or lipid metabolism.  
Increasingly, many miRNAs are found to be involved in the regulation of 
metabolisms in cancer cells. The SREBP-miR-33 regulatory circuit, for instance, 
controls genes which are involved in cholesterol and fatty acid biosynthesis and 
uptake, which include HMGCR and LDLR. Intriguingly, both miR-33a and miR-
33b have been found to be transcribed from the introns of SREBF2 and SREBF1 
encoding genes respectively [278-282]. It will be interesting to see if miR-222 is 
regulated in this manner. Our data showed that miR-221 is not involved in this 
process, which does not come as a surprise since a few studies have revealed that 
miR-221 and miR-222 can have separate targets. MiR-221 and miR-222 are about 
700 base-pairs apart. While they could be regulated by the same promoter and 
transcribed from the same gene, differential splicing from the host gene might be 
responsible for their individual roles. It will be interesting to identify, if any, the 
promoters that regulate the transcription of miR-222. Another possibility is that 
SREBP might upregulate miR-222 indirectly through activation of the regulator 
of miR-222. Invasive breast cancer cells have a higher expression of miR-222 to 
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begin with, so this upregulation might be a different pool of miRNA induced to 
target anti-apoptotic proteins to allow for Statin to exert its function.  
  
It remains to be seen if this „new‟ role of miR-222 is restricted to Statin-
treated breast cancer cells. It will be interesting to treat normal breast epithelial 
cells with simvastatin, perform the various add-back experiments and assess the 
levels of miR-222. A higher dose might be required for normal cells as they have 
a robust homeostatic feedback system which will render them more resistant to 
simvastatin treatment. This will give us an idea of whether the upregulation of 
miR-222 is limited to cancer cells.  
 
Our discovery revealed that the upregulation of miR-222 and 
downregulation of DDX20 represent two new different pathways through which 
Statin exert its function. Our results thus far showed that manipulation of miR-
222 did not affect the downregulation of DDX20 and that the two events function 
differently, but the discovery of miR-222 in Statin-induced apoptosis adds a new 
dimension to exploiting miRNAs in diagnostics and therapeutic purposes. Since 
miR-222 is upregulated upon Statin treatment, I expect to see an upregulation of 
miR-222 in patients‟ sera. One possible application is that miR-222 can be used as 
a marker to predict patients‟ response upon Statin treatment. It is equally possible 
that cancers cells, or in this case, patients who express higher levels of miR-222, 
are more sensitive to Statin treatment.   
 
 
4.4 Conclusions and perspectives 
 
 
In conclusion, I identified two different pathways through which Statin 
can exert its effects. I showed that Statin can downregulate DDX20 through 
canonical MVA pathway. I demonstrated that silencing DDX20 can increase the 
sensitivity of cells to simvastatin-induced cell death. Subsequently, I also showed 
for the first time that Statin treatment can mediate and upregulate the level of 
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miR-222. I also showed that unlike its oncogenic roles, overexpression of miR-
222 lead to the increase cell death of simvastatin-treated cells.   
 
Statin-induced miRNA deregulation has been reported in a few studies. 
However, the study of Statin-induced miR-222 upregulation in invasive breast 
cancers is a first. I believe that this study will continue to grow in the 
characterization of the roles of miR-222 and its impact on Statin effect and target 
identification. Similar studies should also be performed on aggressive breast 
cancer cell lines as well as other aggressive cancers to provide a complete picture 
of Statin-mediated apoptosis in cancers. I also reason that Statin-treatment should 
result in the involvement of many other miRNAs. Thus, microarray studies on 
Statin-induced miRNA deregulation should also be performed, as integrating 
individual miRNA to form complex miRNA regulatory networks will further 
improve our understanding of the role of Statin-induced miRNA deregulation in 
cancers and facilitate novel treatment strategies. The understanding of the exact 
mechanisms for Statin-induced miR-222 upregulation will also provide clues for 
exploiting Statin in breast cancer treatment. I hope, in the near future, that I can 
also better comprehend the roles of miRNAs in breast cancer drug resistance. I 
can integrate this new information with the existing knowledge of the anti-cancer 
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APPENDIX A:  Contributions from research collaborators 
 
Expression of DDX20 is positively correlated with MVA pathway genes. 
 
DDX20 is positively correlated with MVA pathway genes. Correlation between 
17 MVA pathway-related genes and the expression of DDX20 were assessed in 
1325 patients. Among the 17 MVA pathway genes evaluated, positive correlation 
with DP103 gene expression was observed in 8 of them, with HMGCR having the 
most significant positive correlation (Spearman, Rho=0.222, p=2.22e-16), 
followed by HMGCS1 (Spearman, Rho=0.218, p=6.66e-16), ACAT2 (Spearman, 
Rho=0.212, p=4.11e-15), NSDHL (Spearman, Rho=0.194, p=7.95e-13), FDPS 
(Spearman, Rho=0.172, p=2.11e-10), SQLE (Spearman, Rho=0.158, p=5.19e-9), 
IDI1 (Spearman, Rho=0.154, p=1.34e-8), and CYP51A1 (Spearman, Rho=0.122, 
p=7.74e-6) (Figure 3A). HMGCR expression, having the highest correlation with 
DDX20, is subsequently analysed with breast cancer subtypes (Figure ia). 
 
HMGCR is correlated with poor prognosis. Dot plot of HMGCR gene 
expression in breast cancer subtypes.  The gene expression value of HMGCR (y-
axis) is plotted for basal, claudin-low, luminal-A, luminal-B, ERBB2 (HER2+), 
and normal-like breast cancer subtypes. Mann-Whitney test was performed in 
comparing one subtype versus other subtypes. From the panel of 1325 breast 
cancer samples, gene expression of HGMCR was significantly higher in Luminal-
B subtypes than the rest of the subtypes (Mann-Whitney test p=7.58e-12). Basal, 
ERBB2 and Normal-like subtypes have marginally higher expression of HGMCR 
when compared against the rest of the subtypes (Mann-Whitney test p=0.0654, 
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p=0.066, and p=0.0268, respectively). Paradoxically, HGMCR expression level is 
significantly lower in Luminal-A (Mann-Whitney test p=1.95e-5), and in Claudin-
low (Mann-Whitney test p=1.21e-4) subtypes (Figure ib). We subsequently 
looked at the association of HGMCR gene expression with overall and relapse-
free survival using Kaplan-Meier analysis. Using median of HGMCR expression 
to define HGMCR-high and –low groups, a clear separation can be observed in 
overall and relapse free survival curves between the two groups (log rank test, 
p=0.06, and p=0.028, respectively).  This is not surprising since high HGMCR 
expression is associated with Luminal-B, Basal, and ERBB2 subtypes, which are 






















Figure (i). DDX20 is positively correlated with MVA pathway genes. (A) 
Gene expression heatmap of MVA pathway genes and DDX20.  The 1325 breast 
cancer tumors were aligned from the lowest to the highest DDX20 gene 
expression, as shown in the top color bar.  Genes in MVA pathway ([258]) were 
shown on the left of the heatmap, arranged from the gene with most negative to 
the gene with most positive correlation with DDX20 gene expression.  The 
corresponding Spearman correlation result and p-value were shown on the right of 
heatmap.  Red color indicates high gene expression level whereas green color 
indicates low gene expression level. (B) . The subtypes are represented by 
different colors; maroon for Basal, yellow for Claudin-low, light blue for 
Luminal-A, dark blue for Luminal-B, orange for ERBB2 and green for Normal-
like. (C) Association of HMGCR expression with overall and relapse-free 
survival. (Left Panel) Kaplan-Meier plot of overall survival for 252 breast cancer 
patients. (Right Panel) Kaplan-Meier plot of relapse-free survival for 463 breast 
cancer patients. Red color represents group with higher HMGCR expression, 
whereas blue color represents group with lower HMGCR expression.  Median of 
HMGCR gene expression was used to define HMGCR-high and HMGCR-low 
groups.  P-value shown is computed by log-rank test. (Contributed by: Dr Tan 
Tuan Zea, Tony and Professor Jean-Paul Thierry).  
 
 
 
